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BACKGROUND: Chronic diseases like diabetes and metabolic syndrome are increasing 
rapidly in China. The present study was a part of an ongoing prospective follow-up 
project aiming to develop necessary health strategy. 
 
OBJECTIVE: The aim of this study was to evaluate the prevalence of diabetes and 
metabolic syndrome and to identify their associated risk factors among middle-aged and 
elderly participants in Jiangsu province, China. 
 
RESEARCH DESIGN AND METHODS: As the baseline survey of a follow-up 
programme, this population-based cross-sectional study was performed on 3914 adults 
aged 35-74 years living in urban and rural areas of 4 cities in Jiangsu province, eastern 
China. The prevalence of diabetes and metabolic syndrome was assessed according to 
WHO, IDF and modified ATP III criteria. Potential socio-demographic and lifestyle risk 
factors were also analyzed. Data was collected by interviewer-administered questionnaire, 
biophysical assessment and biochemical examination. 
 
RESULTS: Age-Standardized prevalence of diabetes and IFG was 6.8% and 21.0% 
respectively. Family history of diabetes was an important predictor of diabetes in the 
study population. However, BMI was found as the strongest significant risk factor for the 
development of diabetes. The adjusted prevalence of metabolic syndrome defined by 
WHO, IDF and modified ATP III criteria was 12.3%, 21.8% and 31.5%, respectively. 
Gender, age and BMI status were significant risk factors for metabolic syndrome 
independent of definition, while higher education level for WHO MetS, habit of tea 
consumption for modified ATP III MetS were protective factors in the study population. 
The diabetes and metabolic syndrome were more common in female than in male 
(p<0.05). Substantial agreement (κ=0.79) was found between IDF and modified ATP III 
definitions. In addition, weight gain was particularly risk factor for each disorder among 
originally normal weight population (p<0.001). 
 
CONCLUSIONS: Diabetes and metabolic syndrome were highly prevalent in middle-
aged and elderly Chinese population. Community-based strategies for lifestyle 
modification are of great necessity to address the problems. 
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1. INTRODUCTION 
1.1 Worldwide burden of chronic noncommunicable diseases 
 
When infectious disease is still threatening people’s health, chronic diseases, including 
cardiovascular diseases (CVD), diabetes, obesity, cancer and chronic respiratory diseases, 
are nowadays the major cause of death and disability worldwide(1). The report from 
World Health Organization showed that, approximately 35 out of the 58 million deaths 
were related to chronic disease in 2005 (1). Furthermore, these diseases increasingly 
affect people, families and communities globally due to increasing degree of underlying 
determinants for the diseases like globalization, urbanization and population ageing, and 
so on. For example, overweight and obesity in child and adolescent are increasing 
worldwide(2, 3). The total number of people with diabetes is projected to rise from 171 
million in 2000 to 366 million in 2030(4). 
 
In developed countries like the United States, chronic diseases account for 70% of all 
deaths in the country, which is 1.7 million each year(5). Whereas, more than 80% of 
these diseases occurred in low- and middle-income countries(6). In 2006, the estimated 
losses as a result of coronary heart disease, stroke, and diabetes ranged from $20–30 
million in Ethiopia and Vietnam, and near $1 billion in populous countries such as China 
and India(6). 
 
However, another important fact is that a relatively few and preventable risk factors cause 
the majority of the chronic disease burden(1). Unhealthy diet, physical inactivity, tobacco 
use are the most common modifiable risk factors. It is almost the same in men and 
women, similar in every part of the world. In conjunction with non-modifiable risk 
factors (age and heredity), they can explain the majority of new events of chronic 
diseases. 
 
Although chronic diseases are very common, they are invisible. So far, whether the 
global goal for chronic disease prevention and control set by WHO(6) can be achieved in 
the future remains unknown(7). But, convincing evidence indicates that adopting healthy 
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behaviors such as eating nutritious foods, being physically active and avoiding tobacco 
use can largely prevent or control the adverse effects of these diseases. 
 
1.2 Diabetes mellitus 
 
1.2.1 Diagnosis and classification of diabetes mellitus 
 
The recommendations for the classification, diagnosis, and screening of diabetes are 
revised every few years, reflecting updated knowledge from research and clinical 
practice(8). For example, in 1997, the American Diabetes Association (ADA) 
recommended that the cut-off point for fasting plasma glucose (FPG) for diabetes should 
be reduced from 7.8 to 7.0 mmol/l, and arabic numerals should be used for type of 
diabetes instead of roman numerals(9). In 2003, follow-up report from ADA suggested 
the cut point for IFG should be further reduced from 6.1 to 5.6 mmol/l(10). 
 
Based on the latest recommendations from American Diabetes Association (ADA) in Jan. 
2008(11), classification of diabetes mellitus are as follows: 
 
I. Type 1 diabetes (β-cell destruction, usually leading to absolute insulin deficiency) 
II. Type 2 diabetes (may range from predominantly insulin resistance with relative insulin 
deficiency to a predominantly secretory defect with insulin resistance). It accounts for 
about 90-95% of those with diabetes. 
III. Other specific types (genetic defects of β-cell function, genetic defects in insulin 
action, endocrinopathies, and so on) 
IV. Gestational diabetes mellitus (GDM) 
 
Diagnosis criteria for the diabetes are: 
 
Fasting plasma glucose≥126 mg/dl (7.0 mmol/l).  
OR 
Symptoms of hyperglycemia (including polyuria, polydipsia, and unexplained weight loss) 
and a casual plasma glucose≥200 mg/dl (11.1 mmol/l). 
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OR 
2-h plasma glucose≥200 mg/dl (11.1 mmol/l) during an OGTT, using a glucose load 
containing the equivalent of 75 g anhydrous glucose dissolved in water. 
 
These criteria to diagnose diabetes should be confirmed by repeat testing on a subsequent 
day, in the absence of unequivocal hyperglycemia.  
 
1.2.2 Prevalence and trends of diabetes globally 
 
Diabetes is one of the most costly and burdensome chronic diseases of our time and is 
increasing at an alarming rate becoming one of the major public health problems 
throughout the world(12). The adverse effects on health root in the broad spectrum of 
acute and chronic complications of the disease. Diabetes, particularly Type 2 diabetes, 
has risen steadily during recent decades and continues to increase in the future. 
According to the findings from American Diabetes Association (ADA) in 2004(4), the 
prevalence of diabetes for all age-groups worldwide was estimated to be 2.8% in 2000 
and 4.4% in 2030. The total number of people with diabetes is projected to rise from 171 
million in 2000 to 366 million in 2030, which is shown in Figure 1.1(4). 
 
Figure 1.1 Estimated numbers of adults with diabetes by age group, year in the 
world. 
Just taking one specific country as a example, the prevalence of diabetes, impaired fasting 
glucose, and insulin resistance was high and their prevalence continues to increase in the 
United States from two nationally representative samples of the adult population during 
the periods 1988-1994 and 1999-2002(13). 
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The prevalence of diabetes is also substantial in adolescents. For example, a cross-
sectional study in USA(14), using data from National Health and Nutrition Examination 
Survey (1999-2002), found that 0.5% of adolescents reported having diabetes. Of those 
reporting diabetes, 71% were type 1 and 29% as having type 2 diabetes. And, 11% of 
them had impaired fasting glucose levels. In children, an earlier onset of Type 1 diabetes 
has been observed, and also the incidence of Type 2 diabetes among young people is 
increasing(15).  
 
However, the prevalence of diabetes varies in different countries and different ethnic 
groups. Additionally, it is higher in developed countries, but the largest relative increase 
will occur and the greatest impact will be given in the developing countries(8, 16). The 
main reasons are both aging of the population and increasing urbanization(16). 
 
1.2.3 Diabetes in China 
 
Diabetes has become an important public health challenges in developing countries. 
China is the second top country with highest numbers of people with diabetes in the 
world only after India mainly due to both aging of the population and dramatic 
urbanization(4). 
 
During past few decades, several large-scale observational surveys have robustly figured 
out the estimation of diabetes in mainland China. The prevalence of Type 2 diabetes and 
impaired glucose tolerance was reported to be about 1%, respectively among a sample of 
110,660 men and women aged 25 to 74 years living in Daqing City, northeast China in 
1986(17). More representative study, the 1994 China National Diabetes Survey 
examination of 213,515 subjects aged 25 to 64 years yielded prevalence estimates for 
diabetes and impaired glucose tolerance of 2.5% and 3.2%, respectively. And the 
prevalence of diabetes was three times higher then it was 10 years ago(18). More recently, 
InterASIA study conducted in 2000-2001 including nationally representative sample of 
15,540 adults aged 35-74 years, reported that the prevalence of self-reported diagnosed 
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diabetes, undiagnosed diabetes, and impaired fasting glucose were 1.3%, 4.2%, and 7.3%, 
respectively. The age-standardized prevalence of diabetes was higher in the north and in 
urban areas(19). Obviously, the rate increased and it is foreseeable to continue along with 
the time if no intervention in despite of diagnostic criteria were slightly different in 
different studies. 
 
In elderly, reliable results from the 2002 National Nutrition and Health Survey in China 
indicated that adjusted prevalence of diabetes in 9925 subjects aged ≥60 years was 6.8%. 
It was higher in female and in the city(20). 
 
In children and adolescences, figure also from the 2002 National Nutrition and Health 
Survey in China reported that, the overall prevalence of diabetes in subjects aged 5-17 
years was 0.19%. It was higher in urban areas compared to rural counterparts(21). But 
based on another cross-sectional screening program in Beijing area in 2004, the 
prevalence rates of diabetes and IFG among 19,593 schoolchildren were 0.6% and 1.4%, 
respectively(22), which were much higher than national average level two years before. 
 
1.3 Metabolic syndrome 
 
In the last number of years, a great deal of concern has been given to a cluster of    
metabolic abnormalities including abdominal obesity, hyperglycemia, hypertension and 
adipose metabolic disorder identified as metabolic syndrome (MetS). It is regarded as the 
independent risk factor of cardiovascular disease (CVD) and Type 2 diabetes mellitus 
(T2DM)(23-25). These chronic diseases are all characterized with long term, bad 
prognosis and tremendous social and financial burdens. MetS and diabetes are even more 
serious than HIV/AIDS in morbidity and mortality(26). However, there were some 
debates on the use of the term “metabolic syndrome”(27, 28) because it lacks a perfect 
explanation at pathophysiological level although certain CVD risk factors are prone to 
cluster. So far, it is still premature to introduce the current definitions of MetS into 
clinical practice. Single risk factors can be treated appropriately and improved by the 
non-pharmacologic approaches(29). 
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1.3.1 Definitions of metabolic syndrome 
 
Several organizations have issued definitions in an attempt to heighten awareness and 
identify patients who ultimately may be at increased risk for CVD(8). The name of MS 
changed for several times since the first work of Reaven in 1988(30), so did the 
diagnostic criteria. Up to now, dispute on the different definitions of MS never cease. 
Nevertheless, the most frequently used criteria were proposed by World Health 
Organization (WHO)(31), International Diabetes Federation (IDF)(32), and the National 
Cholesterol Education Program Adult Treatment Panel III (ATP III)(33) respectively. 
These definitions share several core features: obesity, insulin resistance, dyslipidaemia 
and hypertension. However, they also include important differences. WHO regards 
insulin resistance as the major underlying pathophysiological abnormality, while ATP III 
and IDF definitions identify abdominal obesity measured as increased waist 
circumference as the key driver of the syndrome. Detailed measurements and categorical 
cutoff points for these three definitions were shown in Table 1.1. 
 
Table 1.1 Diagnostic criteria for MetS from WHO, IDF and ATP III(2005) 
 Measure Categorical cutpoints 
WHO (1999) The presence of glucose 
intolerance, IGT or T2DM 
and/or IR, together with two or 















and/or BMI>30 kg/m2 
TG≥1.7 mmol/l and/or HDLC≤0.9 
mmol/l in men, HDLC≤1.0 mmol/l 
in women 
≥140/90 mmHg 
IGT, IFG, or T2DM 
Urinary albumin excretion 
ratio≥20 mg/min or 
albumin:creatinine ratio≥30mg/g 
IDF (2005) Central obesity (Waist 
circumference ethnically 





(male), ≥80cm (female) for 
Chinese 
 
≥150mg/dl (1.7 mmol/l) or on 







Raised blood pressure 
 
 
Raised fasting glucose 
disorder 
<40 mg/dl(1.03 mmol/l, men), <50 
mg/dl (1.29 mmol/l, women) or on 
specific treatment for this lipid 
abnormality 
SBP≥130 mmHg or DBP≥85 
mmHg or on treatment for 
previously diagnosed hypertension 
Fasting plasma glucose≥100mg/dl 
(5.6 mmol/l) or previously 
diagnosed Type 2 diabetes 
ATP III 
(updated  by 
AHA/NHLBI, 
2005) 
The presence of 3 or more of 
these components: 




Elevated blood pressure 




≥150mg/L (1.7 mmol/l) 
<40 mg/dl(1.03 mmol/l, men), <50 
mg/dl (1.29 mmol/l, women) 
≥130/85 mmHg 
≥100mg/dl (5.6 mmol/l) 
 
1.3.2 Prevalence and trends of metabolic syndrome globally 
 
Globally, the prevalence of metabolic syndrome is high and this prevalence is steadily 
increasing worldwide. Because it is considered as one of important drivers of 
cardiovascular disease (CVD) and Type 2 diabetes as addressed above, the public health 
impact of the syndrome is considerable. Its prevalence varies in various populations due 
to different sociodemographic characteristics and different MetS definitions(34). 
 
In the United States, by using the data from the Third National Health and Nutrition 
Examination Survey and ATP III definition, Earl S. Ford et al. reported that the age-
adjusted prevalence of MetS among US adults was 23.7%, with highest affects in 
Mexican Americans(35). Also using this representative national survey data, Ferranti et al. 
estimated nearly 1 in 10 children aged≥12 years had MetS, and it had a similar 
racial/ethnic distribution with adults(36). 
 
When moving to the Europe, the overall prevalence of the metabolic syndrome in non-
diabetic adults was 15%, by using modified World Health Organization definition of 
MetS. The age-standardized prevalence of MetS was slightly higher in men (15.7%) than 
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in women (14.2%)(37). 
 
In Asia, the overall age-adjusted prevalence of metabolic syndrome was 24.6% (NCEP 
ATP III criteria) in the combined urban and rural population sample in India(38), and 
24.9% in urban population(39). By using Korean National Health Examination and 
Nutrition Survey (KNHENES) data in 1998 and 2001, the prevalence of metabolic 
syndrome among Korean adults was found to be 15-30% according to various criteria of 
metabolic syndrome. Moreover, the rate increased significantly from the year of 1998 to 
2001(40). From information of the Japanese National Health and Nutrition Survey 
(NHNS) in 2003, and according to the Japanese diagnostic criteria, the overall prevalence 
of MetS was discovered to be 22.8% for males and 8.7% for females(41). Moreover, the 
prevalence of MetS was found to vary from <3% in rural Bangladeshi women(42), 15% 
in Thailand(43), and 33.7% in Iran(44). Particular information of metabolic syndrome in 
China was discussed in the next section. 
 
1.3.3 Metabolic syndrome in China 
 
Like other countries undergoing rapid urbanization and nutrition transition in the world, 
westernized lifestyle characterized by a combination of excessive energy intake and 
inadequate physical activity is becoming more and more prevalent in China during few 
decades of years. As a result, metabolic syndrome has been one of important public 
health problems. And also, this condition has impact not only on adults, but also on 
children and adolescents, having more effect in urban area than in rural areas in despite of 
different degree. This can be demonstrated from several available studies conducted in 
China.  
 
For example, study conducted in 11 provinces in 1992 indicated that the prevalence rate 
of metabolic syndrome was high (13.3%, 12.7% in males, 14.2% in females), and it 
increased with age(45). From another study conducted in eastern China in 2002, the 
prevalence of the syndrome among adults without diabetes was 34.3% for men, 24.1 for 
women in urban areas, 2.7% for men and 11.4% for women in rural areas, when using 
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modified ATP III definition(46). Based on survey in one district in Beijing City in 2005, 
the standardized prevalence of MetS was found to be 13.4%, which was slightly lower 
than overall rate in Beijing and Shanghai(47). But in Jiangsu province, the prevalence 
was reported as 15.9% (standardized) in adults aged above 20 years in 2006(48). 
 
In rural area, the age-adjusted prevalence of MetS for adults 25 to 64 years old was 3.2%, 
4.9%, and 3.9% in men and 7.2%, 11.5%, and 10.9% in women, respectively in the 
sample of 18,630 adults 25 to 64 years old from Anhui Province, according to ATP III, 
modified ATP III and IDF criteria(49).  
 
In children and adolescents, MetS was still relatively low in general, but MetS prevalence 
among Chinese overweight adolescents was similar to those living in the USA. This was 
the estimation from national representative sample in the 2002 China National Nutrition 
and Health Survey. Li et al. reported that the overall prevalence of the metabolic 
syndrome in 2761 adolescents aged 15-19 years was 3.7% by applying the criteria for US 
adolescents. Urban boys had the highest rate (5.8%) compared with girls and rural 
youngsters(50). In addition, a school-based survey in Beijing in 2006 found that the 
overall prevalence of MetS among adolescents aged 14–16 years was 3.3%, and it 
increased significantly with BMI(51). But, the MetS has reached a high level in some 
areas today. For example, MetS has already affected 10.3% obese children and 
adolescents in Zhejiang Province, southeast of China(52). 
 
1.4 Associated factors for diabetes and metabolic syndrome 
 
Although the precise etiology of most cases of diabetes and MetS remains uncertain, 
Contributing factors have been well established and well known(1). Some like lifestyle 
factors have been further confirmed by a great deal of intervention researches. It is 
considered that underlying determinants like urbanization, population aging lead to 
appearance of a set of risk factors described below. And those risk factors cause the 
disease by the intermediate of raised blood pressure, elevated glucose level, abnormal 
blood lipids, and so on. The relationship between the major modifiable risk factors and 
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the diseases is similar in all regions of the world.  
 
There are three points which need to be mentioned here. One is that diabetes and 
metabolic syndrome, complex metabolic diseases, share almost all of common risk 
factors. And also, metabolic syndrome itself is thought to a major risk factor for Type 2 
diabetes. The second, the degree and distributions of these risk factors are diverse in 
different area and populations. The third, these risk factors, which include genetic, 
environmental, and lifestyle ones, interact with each other, possibly having synergy on 
the occurrence of diseases, although some of them are independent determinants. 
 
Compelling evidence from metabolic studies, large prospective observational studies, and 
clinical trials indicate that unhealthy diet, overweight/obesity, and sedentary lifestyle are 
major contributors to the diabetes epidemic(8). So do the metabolic syndrome. In 
addition, there are also other modifiable risk factors including smoking, alcohol drinking, 
inflammation, etc(53, 54). These are the target of intervention approaches.  
 
1.4.1 Socio-demographic factors 
 
These factors include age, gender, ethnicity, family history of diabetes, etc. Of course, 
they belong to non-modifiable factors but still worth mentioning solely.  
 
The risk of diabetes, metabolic syndrome and its components increases markedly with 
age. Even with identical BMI, the elderly is much more likely to develop the disease than 
the youth. And in recent decades, the age of onset has moved down into younger adults 
and even adolescents(54). Sex and racial differences were often observed in many studies 
on diabetes and MetS, regarding the rate of disease, the distribution of risk factors, etc. 
 
People who have family members with diagnose of Type 2 diabetes are at a greater risk 
for developing it themselves. Nevertheless, having a genetic disposition towards diabetes 
is not a guarantee of developing diabetes. Modifiable factors play an important role in 
determining the final result on the basis of giving genetic background. 
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1.4.2 Overweight and obesity 
 
Finding from epidemiological studies have repeated confirmed a strong positive 
association between excess adiposity and risk of developing Type 2 diabetes(8). The 
increasing prevalence of obesity was the single most important risk factor and largely 
responsible for the increase in the prevalence of Type 2 diabetes(16, 55). Greater weight 
means a higher risk of insulin resistance, because fat interferes with the body's ability to 
use insulin. Furthermore, interventions aiming at reducing obesity also reduce the 
incidence of Type 2 diabetes and metabolic syndrome. Body mass index (BMI) is the 
most commonly used parameter for overweight and obesity. However, several studies 
indicated that waist circumference or waist-to-hip ratio, which reflects visceral 
(abdominal) fat, may be better indicators of the risk of developing Type 2 diabetes than 
body mass index(54). 
 
The prevalence of overweight and obesity is increasing dramatically in adults in the 
world. But more important, the increasing prevalence of obesity in children and 
adolescents is a particular concern(16). 
 
Other than excess adiposity, weight gain is also an important predictor of developing 
Type 2 diabetes and metabolic syndrome. Just one example, based on data from a large 
prospective cohort, Oguma et al. found that, weight gain significantly increased the risk 
of Type 2 diabetes, and that a low initial BMI does not ameliorate the increase in risk of 
type 2 diabetes with weight gain(56). 
 
1.4.3 Dietary factors 
 
Diet is one crucial aspect of lifestyle. Messages from a large number of epidemiological 
studies indicate that unhealthy diet including a high total calorie, low dietary fiber intake, 
a high glycaemic load, a low polyunsaturated to saturated fat ratio, etc. is thought to 
contribute to the development of chronic diseases including diabetes and metabolic 
syndrome. Studies found that, high fiber content, n-3 fatty acids, and antioxidants, as well 
as phytochemicals from olive oil, legumes, whole grains, fruits, and vegetables, might be 
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responsible for its beneficial effect on the prevention and control of diabetes and 
metabolic syndrome. 
 
Besides, unhealthy diet can lead to MetS components like overweight/obesity, high blood 
pressure, dyslipidemia, indirectly and thereby lead to the occurrence of metabolic 
syndrome. 
 
Convincing evidence from the prospective studies consistently showed a reduced risk for 
high intake of whole grain foods or cereal fiber on the development of Type 2 diabetes 
(57). Actually, diet together with other lifestyle modification is the basis in the prevention 
and management of Type 2 diabetes. A study(58) even documented that adjustment of 
diet composition without weight loss or pharmacologic intervention could improve the 
hyperglycemia of Type 2 diabetes. 
 
1.4.4 Physical activity and sedentary lifestyle 
 
Physical inactivity has been found, in both cross-sectional and longitudinal studies, to be 
an independent predictor of Type 2 diabetes in men and women(54). It is also a major 
contributor to the global increase of obesity. Both low sedentary and high exercise 
activities contribute to increased energy expenditure, improved weight control and 
prevention of obesity(59). Increased physical activity can prevent the weight gain 
associated with aging at least two times greater in individuals who were more active 
compared with those who were inactive(60). Evidence from epidemiological studies 
indicates that physically active persons have a lower incidence of diabetes and metabolic 
syndrome. Physical activity can reduce 35% of the risk for diabetes, which was found 
from a literature review(60). It can also reduce the risk of Type 2 diabetes in people with 
prediabetes (IGT and/or IFG) independent of diet or weight loss. 
 
Other than the prevention, exercise has been recommended a treatment for Type 2 
diabetes, metabolic syndrome, and some other chronic diseases. Moreover, the 
effectiveness of physical exercise depends on the type frequency, the intensity and the 
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In recent years, it has been demonstrated that chronic, low-level tissue inflammation 
related to obesity contributes to insulin resistance, the major cause of Type 2 diabetes. 
And also, Chronic subclinical inflammation is associated with metabolic syndrome, as 
indicated by an increase in circulating levels of proinflammatory cytokines, which was 
supported by Insulin Resistance Atherosclerosis Study (IRAS) and follow-up(61). So far, 
inflammatory markers discussed in the researches include C-reactive protein (CRP), 
TNF-α, plasminogen activator inhibitor (PAI)-1, fibrinogen, and so forth. 
  
For example, C-reactive protein (CRP) was regarded as a sensitive marker of systemic 
low-grade inflammation and was an important predictor of type 2 diabetes(62). 
 
1.4.6 Other non-modifiable factors 
 
In this sort, they comprise history of gestational diabetes, polycystic ovary syndrome in 
female, birth weight, and so on. 
 
Gestational diabetes affects about 4% of all pregnant women. It begins when hormones 
from the placenta make the mother insulin resistant. Women who had gestational diabetes 
have substantially higher risk of developing Type 2 diabetes in later life. Their babies are 
also at some risk for developing diabetes in later life. 
 
Another example, a meta-analysis(63) including 14 studies (132,180 persons) indicated 
that U-shaped, not linear relationship existed between birth weight and diabetes risk in 
later life, which meant low birth weight and high birth weight were associated with 
increased risk of diabetes to the same degree. 
 
1.5 Follow-up study on metabolic syndrome and diabetes 
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Follow-up study discussed here means observational cohort study, which observes the 
outcomes of exposure over a period or at intervals in persons exposed to risk, without any 
intervention measurements. Because exposure information is collected before outcomes, 
it is more reliable and more powerful for testing casual hypothesis than cross-sectional 
study. Therefore, it is worth conducting if conditions permit. 
 
During the past few years, several different definitions for MetS have been issued with 
the main purpose to identify individuals at high risk for cardiovascular diseases. 
Prospective follow-up studies regarding metabolic syndrome as exposure have been 
performed in USA, Finland, Italy, and so on (64-66). They, but not all, shown that MetS 
was related to increased risk of cadio-cerebrovascular diseases such as stroke(65), 
coronary heart disease, cardiovascular events(66), cardiovascular mortality(67), heart 
attack and mortality(64) and so forth. MetS in childhood was also associated with adult 
cardiovascular disease in the future(68).Moreover, researchers also found that MetS 
predisposed to depressive symptoms(69), impaired cognitive function(70). 
 
Evaluation on the predictive ability of different MetS definitions can also be performed in 
follow-up study, as they did in USA(71) and in Italy(72). 
 
As demonstrated above, not all studies consistently drew the same conclusions. For 
example, it was reported that MetS was a significant predictor of CVD and Type 2 
diabetes, especially the latter in England(73). And also, Wang et al. reported MetS can 
predict incident diabetes in Beijing Chinese population(74). But, in another study, 
Cameron et al. called for a debate by drawing an opposite conclusion that a single fasting 
glucose measurement was more effective and efficient than MetS by published 
definitions in predicting incident diabetes in giving adult population(75). 
 
Unlike metabolic syndrome, follow-up study which looked on diabetes as exposure has 
been relatively scarce possibly because diabetes itself is a serious disease normally as 
endpoint. Nevertheless, some studies evaluated diabetes as predictor of other diseases or 
mortality. The researchers found that diabetes increased the risk of endometrial cancer in 
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Norwegian women during 15.7 years of follow-up(76), diabetes had a strong synergistic 
effect together with depression on excess mortality(77). There were also some studies 
which evaluated health management of diabetic patients or complications occurrence. For 
instance, many children and adolescents with T2DM were found insufficient adherence to 
diabetes centers in general practice and lifestyle intervention as sole treatment was not 
often useful for long-term metabolic control(78). 
 
1.6 Intervention epidemiology 
 
Leaving high risk groups or patients alone after awareness is unacceptable, and 
prevention is the best management for them. It is particularly important to effectively 
implement and strengthen population-based primary prevention strategies since it is the 
most cost-effective form of health care(79). The prevention of diabetes by the change of 
the lifestyle or if necessary some drugs become a major concern worldwide(57, 80, 81). 
Actually, several intervention studies, including lifestyle modification and drug treatment, 
have been done and consistently demonstrated the progression to Type 2 diabetes can be 
prevented or deferred in those persons at high risk from diverse racial backgrounds and 
across all age groups.  
 
The intervention studies were performed both in developing countries like China(82), 
India(81) and in developed countries like Sweden(83), Finland(80, 84, 85), the United 
States(86). 
 
Most interventions on diabetes had a couple of similar characteristics: (a) Intervention 
measurement mainly included dietary change (less fat intake, more vegetable 
consumption, more fiber intake, etc.), or exercise training, or a combination of both. (b) 
Target population was individuals with impaired glucose tolerance (IGT), a particularly 
high risk group. (c) If drug was used as a way of prevention of diabetes in the 
interventions, generally it was metformin. (d) The conclusions were consistent, i.e. these 
intervention measurements could reduce the incidence of diabetes in local population at 
different degree. But, detailed approaches used to implement the intervention were 
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different from study to study.  
 
For example, Indian Diabetes Prevention Programme (IDPP) has demonstrated that 
moderate but consistent lifestyle modification or therapeutic intervention with metformin 
could prevent or delay progression of IGT to diabetes with relative risk reductions of 28.5 
and 26.4%, respectively(81), and these kind of intervention were cost-effective(87). 
Furthermore, the most recently intervention on diabetes was found as DE-PLAN project 
in Europe(88), which involved 17 European countries so far, and it is still on the process.  
 
To sum up, intensive diet and lifestyle modification can largely reduce the risk of Type 2 
diabetes which is more effective than drugs although both had encouraging effects. In 
addition, diet and lifestyle modification are considered the cornerstone in the prevention 
and management of Type 2 diabetes(8).  
 
Because of sharing some common risk factors, intervention on metabolic syndrome was 
similar with the diabetes prevention. Lifestyle changes (diet and physical activity) were 
regarded as the first-line approaches and these approaches were proven to be effective 
(89-91). Since MetS is a combination of cardiovascular disease risk factors, its 
intervention or treatment actually was aiming at reverse of single metabolic abnormities. 
So, very few studies have been conducted especially targeting at MetS up to now. Effect 
of intervention on MetS and its components were also analyzed in diabetes prevention 
study(89, 92). 
 
But, one important issue that is worth of note is post-study sustainability of intervention. 
Although most of these studies were found effective in achieving short term effect, very 
limited evidence can be found regarding long-term effect of intervention and maintenance 
of lifestyle correction. 
 





As stated above, metabolic syndrome and diabetes have reached epidemic proportion and 
are increasing rapidly especially in countries with economic transition like China in 
which dramatic urbanization and nutrition transition are occurring(93). Actually, chronic 
diseases such as metabolic syndrome, diabetes have been identified as significant public 
health problems in China since early 1990s. A MetS study which was conducted in 11 
provinces in 1992 indicated that the prevalence rate of metabolic syndrome was high 
(13.3% total, 12.7% in males, 14.2% in females, mean age 50.6 years old), and it 
increased with age(45).  
 
In eastern China, Jiangsu province is relatively developed area with more health 
challenges associated with socioeconomic development. According to the 2002 National 
Nutrition and Health Survey in China, the prevalence of the MetS components in adults 
in Jiangsu province was quite high. Standardized prevalence rates of hypertension, 
diabetes and dyslipidemia in representative subjects aged ≥18 years were 19.3%, 2.6% 
and 17.8%, which were much higher in elderly groups. The prevalence rate of 
overweight/obesity was 29.0% in general(94). Due to constant increase of aging people, 
developing economics and consequential changes in lifestyle and diet, etc, it is fully 
reasonable to assume that the hazard of MetS is becoming more serious than before. In 
order to develop sound health policy to cope with the challenges related to lifestyle 
change, we need to identify the extent of the problem and its risk indicators. 
 
However, very limited data is available for the prevalence of MetS and diabetes in large 
scale, population-based study in China. Even within Jiangsu province, little is known and 




Overall objective was 
To evaluate the prevalence of diabetes and metabolic syndrome among middle-aged and 
elderly participants in Jiangsu province, China. Furthermore, its associated risk factors 
were also analyzed. 
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Specific aims were 
1. To estimate the prevalence of diabetes, IFG and hyperglycemia in Chinese adults. 
2. To determine the association between selected socio-demographic, behavioral 
variables and diabetes in Jiangsu, China. 
3. To describe the sex- and age-specific prevalence and distribution of metabolic 
syndrome among adults aged 35-74 years in Jiangsu province, China. 
4. To identify the determinants for metabolic syndrome using WHO, IDF and ATP III 
definition, respectively. 
5. To assess the agreement between different definitions of metabolic syndrome. 
6. To investigate the correlation between FPG and other variables including inflammation 
biomarkers in selected subsample. 
 
3. MATERIALS AND METHODS 
 
It was population-based cross-sectional study focused on the prevalence, main risk 
factors and their degrees of MetS and diabetes in Jiangsu province. Data was collected 
through questionnaire interviews, body examination on anthropometry variables and 
blood analysis. Anthropometric test and blood sampling were conducted at the time of 
interview. 
 
3.1 Brief description of the study area 
 
3.1.1 Geography and climate 
 
Jiangsu, an eastern province in mainland China, covers an area of 0.1 million square 
kilometers (1.06% of the total area of the country). There are two great rivers flowing 
through the whole province: Yangtze River from west to east and Beijing-Hangzhou 
Grand Canal from north to south. With Yellow Sea to its east, Jiangsu adjoins Anhui and 
Shandong provinces in the west and north respectively, with Zhejiang province and 
Shanghai Municipality as its neighbors in the southeast (Figure 3.1). Located in the 
prosperous Yangtze Delta, Jiangsu has a large area of plain as its typical topography, and 
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dotted with two of the top five freshwater lakes in China. Jiangsu thus enjoys the 
superiority of its natural condition and lays a solid economic foundation. 
 
Figure 3.1 Geographical location of Jiangsu province in China 
 
Situated in a transition belt from a subtropical to temperate zone, the province has a 
typical monsoon climate(95). Generally, it is mild with moderate rainfall and clear 
distinction of the four seasons. 
 
3.1.2 Socio-demographic characteristics 
 
Jiangsu consists of 13 prefectures which include 54 city districts and 52 counties. The 
total population in the province is 75.5 million, with balanced gender ratio(95). It is 
populated by Han (99.67%), Hui, Man and other ethnic groups. 
 
Jiangsu is one of the most densely populated provinces in China. And also it is one of the 
most economically developed areas in China, with 10.3% of national GDP only after 
Guangdong Province. 
 
Infant mortality rate is 5.95‰ and mortality rate of children under 5-year is 7.62‰(95). 
Average life expectancy in Jiangsu is 74.13 years. The proportion of the population ≥60 
years in 2000 was 8.8%, and it is projected to be 20.5%, 29.0% in 2020 and 2040, 
respectively. It is characterized by female elderly dominating the proportion, higher 
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growth rate of the elderly than that of economic development and unbalanced 
distribution(96). 
 
3.1.3 Urbanization and nutrition transition 
 
At present, more than half of the population lives in the cities and towns. And also, 
Jiangsu is one of the provinces in China with highest speed of urbanization. Urbanization 
level increased from 20% to 50% only within 15 years (97). 
 
Rapid urbanization has important impact on nutrition. The long-term trend of nutrition is 
a shift from traditional Chinese diet towards a diet with high fat, high energy density and 
low dietary fiber(98). These changes resulted in rapid increases the prevalence of 
overweight/obesity and dietary-related chronic non-communicable diseases in urban 
residents. 
  
3.1.4 Health challenges in adults in Jiangsu province 
 
Infectious disease decrease rapidly in Jiangsu. In contrast to that, owing to continuous 
aging of population, urbanization, unhealthy lifestyle, etc., chronic noncommunicable 
disease, including cardiovascular diseases (CVD), diabetes, cancer, etc. has been the most 
serious public health problems in the province. It is responsible for about 70% of deaths 
in the province(99). It is estimated that about 7 million hypertension patients, 2.2 million 
people with diabetes, 0.6 million people with coronary heart disease in the whole 
province at present(99). 
 
3.1.5 Health services 
 
There are 1061 hospitals and 153 Centers for disease prevention and control, 188 
community health centers, 32 medical training institutions, 335 thousand health 
professionals and workers in the province(95).  
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So far, institutions and personnel for prevention and control of chronic diseases have 
been established gradually. Sentinel points and surveillance system on such diseases are 
also being set up. A number of epidemiological studies on chronic diseases have been 
conducted, which serve as the basis of planned intervention strategy.  
 
In south of Jiangsu, Taicang is one of national demonstration areas for the prevention and 
control of chronic noncommunicable disease since the 1990s. Its working mode has been 
improved and generalized nationwide that integrated prevention and control network 
based on the community health centers, led by public health system, planed by local 
government. 
 
3.2 Study design and population 
 
This population-based cross-sectional study was conducted in both urban and rural areas, 
north and south in Jiangsu province, China. The study population was adults of both 
gender aged 35~74 years, who were residing in the province. Pregnant women, physically 
or mentally disabled person unable to follow simple questions and examinations were 
excluded. 
 
3.3 Sampling method 
 
3.3.1 Sample size calculation 
 
Sample size of the present study was estimated based on the formula below: 
N= (uα / δ) 2 p (1-p)  
In this formula, 5% significance level (α=0.05) and 1% allowable error (δ =0.01) was 
assumed. Prevalence (p) of diabetes and metabolic syndrome among adults in Jiangsu 
province was estimated as 5.5% and 10%, respectively according to previous literatures 
available in Jiangsu or other areas with similar socioeconomic levels. So, the calculated 
sample size was 1997 and 3457, respectively. In addition, the sample size was added by 
90% response rate to compensate for possible losses and refusals, leading to a modified 
sample size of 2219 and 3841 subjects, respectively. 
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The final sample size in the survey was 3914, which was larger than any one of 
theoretical values and could meet the requirement of analysis. 
 
3.3.2 Sampling procedure 
 
In the current study, four investigation sites were selected by multistage stratified cluster 
random sampling in the year of 2002 or so (initial time is different in different 
investigation sites, but within one year). The stratification factors are sex and age (35~74 
years, 10 years difference between near age groups). Other demographic factors 
(urban/rural, rich/poor) were also be considered.  
 
There were 4 steps in the process of multistage stratified cluster random sampling in the 
present study. Step 1: 54 city districts and 52 counties in 13 prefectures in the province 
were divided into two groups based on the geographic and economic status, i.e. the north 
(low economic level) and south (high economic level). Step 2: among them, 4 city 
district/counties were randomly selected, which were located both in south and north. 
Step 3: All the urban communities or villages in each given area were listed with a 
random number, and the urban community/village with smallest number was selected 
respectively from each area. Step 4: all of the residents aged 35-74 years without 
pregnancy, physically or mentally disabled who were living in the selected 
community/villages were put on the list. Sex and age group balance was cautiously 
considered in this step. Only one person was selected in each family to reduce the 
problem associated to clustering of some risk factors related to genetic predisposition, 























Both male and female residents aged 35~74 years who were randomly selected and also 
consented to participate into the baseline study in these sites in Jiangsu, China. 
Exclusion criteria: 
People who were not qualified by inclusion criteria were excluded from the study. And 
also, pregnant women, physically or mentally disabled person unable to follow simple 
questions and examinations were excluded. 
 
3.4 Data collection 
 
3.4.1 Pre-testing of questionnaires 
 
Questionnaire was developed according to literatures and related experience. Before the 
start of large-scale survey, pre-testing of questionnaires was conducted among 50 
subjects in local community to test the feasibility and reliability of the questionnaire.  
 
A couple of questions in the questionnaire were modified or deleted in consideration of 
acceptance, relevance of the answers, time needed, and difficulty to answer, and so on. A 
rearranged questionnaire was used in the final study. 
1 urban 
















3.4.2 Interviewer-administered questionnaire 
 
In local health service centers, face-to-face interviews were conducted by well-trained 
investigators. The questionnaire included general information, demographic variables, 
history of main diseases related to lifestyles, physical activity, etc. After finishing the 
interview, the investigators were also requested to give their general estimation (how 
reliable the collected information was) on the answers of the participants. And also, 
quality controller wrote down corresponding inspection results (qualified or not) as well. 
 
General information, demographic features: it included name, sex, age, occupation, 
education, economics status, etc. 
History of main diseases related: the participants were asked about some information 
regarding medical history (hypertension, diabetes, hyperlipidemia, obesity, and so on). 
History of drug medication was also involved. 
Family history of diseases: it was defined as having a father, mother, bother, sister, son or 
daughter with diagnosed diseases with regard to hypertension, diabetes, hyperlipidemia, 
obesity, CVD, cancer, and so on 
Lifestyle: it included smoking (smoking status, intensity, duration, type of tobacco used, 
second-hand smoking, etc), alcohol intake (drinking status, intensity, type of alcohol, 
experience of stopping drinking, etc), diet behaviors (frequency of various food and 
beverages consumption now and ten years ago) 
Physical activity: it assessed frequency and intensity of physical activity, comparison 
with past time, and other people during both leisure time and work. 
 
3.4.3 Biophysical assessment 
 
Height, weight, waist and hip circumference, and blood pressure were included in this 
section. Height was measured by using well-mounted stadiometer without shoes to the 
nearest 0.1 cm. Weight was measured with light clothing and without shoes by an 
adjusted scale and recorded to the nearest 0.5 kg. The body mass index (BMI) was 
calculated as the weight (kg) divided by the square of the height (m). Height, weight, 
waist and hip circumference were taken twice. Waist circumference was measured at 1 
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cm above the level of navel at minimal respiration, and hip circumference at the level of 
maximum posterior extension of the buttocks with a tape which was calibrated weekly. 
Waist and hip circumference were recorded to the nearest 0.1 cm. Blood pressure was 
measured on the right arm in the sitting position for 3 times by using standard mercury 
sphygmomanometer, after 5 minutes of rest. The first and fifth Korotkoff sounds were 
recorded and the mean value of three measurements was used for analysis. All 
measurements were taken by trained health investigators in examination rooms. 
 
3.4.4 Biochemical examination 
 
All participants were kindly requested to take venous blood samples after fasting for at 
least 8 hours. The fasting time was further verified before the blood specimen was taken. 
Blood was collected in 3 different tubes. Aside from samples in EDTA tube, other 
samples in non-anticoagulant and fluoride tubes were centrifuged in local site within 3 
hours to separate plasma. All samples were then refrigerated and stored at -20 ºC until 
laboratory assays could be done. Fasting plasma glucose (FPG), total triglyceride (TG), 
total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density 
lipoprotein cholesterol (LDL-C) were measured in all of these blood samples. They were 
measured by Automatic HITACHI7020 Biochemical Analyzer. And other parameters 
like fructosamin, serum uric acid, lipoprotein a, Apo A, Apo B, C-reactive protein, leptin, 
insulin to be measured were measured in a subsample of participants. Quality control of 
the laboratory was assessed internally and externally. 
 
3.4.5 Survey procedures 
 
The protocol, the preparation of questionnaire and survey guideline was finished by 
Provincial Center for Disease Prevention and Control, and School of Public Health, 
Suzhou University. Uniform investigation plan was established. Identical questionnaire 
and other important survey equipments were provided by Provincial CDC. 
 
After sampling, local centers for disease prevention and control were contacted in the 
four selected areas. Investigators together with health professionals were trained by 
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meeting in local CDC in each site. At the same time, selected subjects were informed to 
participate into the survey by local leaders in the communities or villages beforehand. 
Residents were also encouraged to participate by health professionals and workers. 
Normally, three days were spent on the fieldwork survey in each community or village.  
 
On the first day, all of the questionnaires, equipments and materials needed were 
prepared and transported to local health service centers by CDC investigators. 
 
On the second day, invited residents went to the local health service center after overnight 
fasting. In local health service centers, face-to-face interviews were conducted by well-
trained investigators. Anthropometric test and blood sampling were also performed in the 
examination rooms at the time of interview. 
 
On the third day, some residents who didn’t attend the survey on the previous day due to 
various causes such as employment, not fasting, etc. were invited to participate again. 
And also, the information collected by questionnaire, body examination was checked 
with the participants in case of doubt. 
 
During the fieldwork survey, all the organizers or investigators in the study discussed 
fieldwork problems they met by meeting or group discussion. 
 
3.4.6 Health personnel training and field work supervision 
 
These two components were important parts of survey to guarantee the quality. 
Investigators were selected from personnel working in local CDC or health service 
centers with experience of epidemiological survey.  They were trained by meeting in 
local CDC in each site. The background, objectives, the content of investigation, 
requirement of interview and examination were introduced in the meeting. And also, the 
guideline and handbook of survey were distributed. After the training, qualified 
investigators were allowed to attend the survey. 
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The fieldwork was supervised by professionals from quality control group with regard to 
the data collection, checking lab results, data entry and management, checking of death 
causes. Errors found could be corrected. 
 
3.5 Categorizations of metabolic syndrome, diabetes and IFG 
 
In the present study, three different diagnostic criteria including the WHO, IDF and 
modified ATP III definitions(31-33) were all used to identify participants with metabolic 
syndrome in order for comparison and judgment. Detailed measurements and categorical 
cutoff points for each definition were shown in Table 1.1. 
 
According to the latest recommendations of the American Diabetes Association(11), 
participants were defined as having diabetes based on: 
1. Their fasting plasma glucose levels≥7.0 mmol/l. 
2. If they answer “yes” to the question about whether they were ever told by a doctor that 
they had diabetes other than gestation period.  
 
Likewise, impaired fasting glucose (IFG) was defined when: 
1. Fasting plasma glucose level between 5.6 to <7.0 mmol/l, and also  
2. Subjects reporting to use any glucose-lowering agents were considered as diabetic.  
3.6 Statistical methods 
 
3.6.1 Data management 
 
All of the information collected by questionnaire, medical examination and biochemical 
analysis were entered into computer by using Epidata 3.0. The importing procedure is 
congruously provided by Provincial CDC. All collected data were stored in a computer 
database. A trained team checked the recorded information for missing values (which 
should be avoided during fieldwork) and data entry errors. 
 
3.6.2 Data handling 
 
The definitions and classifications of various measurements can be found in Table 1.1. 
Numerical data were described by mean and standard deviation, compared by t test if 
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they were normally distributed. Categorical data were expressed as frequency and 
percentage and compared by Chi-square test or non-parametric tests between different 
subgroups. P<0.05 was considered significance and probability values were two-sided. 
Data analyses were conducted mainly using the SAS System (version 8.1, SAS Institute, 
Cary, NC). 
 
The prevalence of diseases was calculated and standardized by using the data of the 5th 
National Census (in the year of 2000)(100). A multivariable logistic regression was 
performed to identify associated factors for diabetes and metabolic syndrome 
(selection=stepwise, sle=0.1, sls=0.1). Logistic model was also used for controlling 
potential confounders such as sex, age, BMI, smoking, alcohol drinking, educational 
level, and family history of chronic diseases based on previous publications. The 
multivariate-adjusted ORs and 95% confidence intervals were presented. Agreement 
between different MetS definitions was evaluated by the kappa statistic (poor, κ ≤ 0.20; 
fair, κ = 0.21 to 0.40; moderate, κ = 0.41 to 0.60; substantial, κ = 0.61 to 0.80; very good, 
κ > 0.80)(101).  
 
Relationship between fasting plasma glucose level and other parameters were analyzed 
by simple and partial correlation analysis. Since the distribution of CRP was skewed, a 
logarithmic transformation (log 10) was performed and used in simple and partial 
correlation analysis. Potential confounders such as age, area, BMI, education, family 
history of diabetes, smoking, drinking, and sedentary lifestyle were adjusted in multiple 
models. The international classification of adult BMI categories according to World 
Health Organization (WHO) was made as underweight (<18.5 kg/m2), normal weight 
(18.5–24.9 kg/m2), overweight (25–29.9 kg/m2) and obesity (30 kg/m2 or greater)(102). 
 
3.7 Ethical clearance 
 
Ethical clearance was obtained from the Norwegian Research Ethical Committee. 
Approval to conduct this study was also obtained from both Jiangsu Provincial CDC and 
local official institutions. The objectives of the study and methods to be used were 
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explained sufficiently to the participants who were treated with respect for their dignity. 
They were reassured about the confidentiality of data. Folding screens will be used to 
isolate subjects. Male and female participants were arranged to stay in different separate 
rooms when conducting anthropometric measurements. In consideration of safety for 
both subjects and doctors, disposable hypodermic syringes, gloves and other necessities 
were used while taking blood samples. 
 
The investigation initiated only after getting written informed consent from the 
participants of both sexes (shown in appendix). They were never pushed to do it. All the 
participants were free to quit from the research at any time. The questionnaires and 
laboratory documents were kept at Jiangsu Provincial CDC securely. Likewise, the blood 
specimens were frozen and stored. All of the tests on blood were done for research 
purpose. Due to the need of follow-up, the contact information like names and address 
were kept in the research files. However, they were kept away from data and handled by 
other unrelated researchers. All of the information will have the name and address 
removed so that the participants could not be recognized from it when the follow-up 
research is finished. 
 
The written results of medical examination were distributed and explained to participants 
themselves in time. They were free to discuss their health results with their doctors. And 
also, they were encouraged to raise health questions and the questions would be answered 
individually. Medical suggestions (nutrition, lifestyle modification, etc) were also 
delivered. Anyway, the subjects and target population would benefit from the research 
potentially although our project didn’t provide intervention or medication directly. Those 










4.1 Basic description of study sample 
 
4.1.1 Description of baseline characteristics 
Table 4.1 Baseline characteristics of 3914 study subjects by gender from Jiangsu 
Province, China 





Continuous variables    
  Age (years) 54.3±10.9 53.0±10.8** 53.5±10.9 
Waist circumference (cm) 80.7±9.8 79.3±9.6** 79.9±9.7 
Hip circumference (cm) 93.7±7.5 94.3±7.4* 94.0±7.5 
WHR 0.86±0.07 0.84±0.07** 0.85±0.07 
BMI (kg/m2) 23.1±3.4 23.8±3.4** 23.5±3.4 
  SBP (mmHg) 127.9±20.2 125.5±20.6** 126.6±20.5 
DBP (mmHg) 79.6±11.0 76.9±10.4** 78.1±10.7 
FPG (mmol/l) 5.43±1.46 5.60±1.67** 5.52±1.58 
Cholesterol (mmol/l) 5.27±1.24 5.45±1.37** 5.37±1.32 
TG (mmol/l) 1.78±1.28 1.84±1.09 1.82±1.18 
HDLC (mmol/l) 1.32±0.47 1.36±0.41* 1.34±0.44 
LDLC (mmol/l) 3.17±1.07 3.20±1.09 3.19±1.08 
lipoprotein a (mg/l) 463.8±235.2 490.3±204.7** 478.6±219.1 
Apo A (g/l) 1.79±0.62 1.92±0.58** 1.86±0.60 
Apo B (g/l) 0.71±0.27 0.76±0.28** 0.74±0.28 
Categorical variables    
Education**    
Illiterate 202 (11.6) 930 (42.9) 1132 (28.9) 
Primary school 615 (35.2) 622 (28.7) 1237 (31.6) 
Middle school 792 (45.3) 576 (26.6) 1368 (35.5) 
Junior college/university 139 (8.0) 38 (1.8) 177 (4.5) 
Income (RMB Yuan/year) **    
<6000 1091 (62.4) 1490 (68.8) 2581 (65.9) 
6000-15000 532 (30.4) 589 (27.2) 1121 (28.6) 
15000-25000 90 (5.2) 67 (3.1) 157 (4.0) 
≥25000 35 (2.0) 20 (0.9) 55 (1.4) 
Smoking (yes) 1194 (68.3) 81 (3.8) ** 1275 (32.6) 
Alcohol drinking (yes) 983 (56.2) 130 (6.0)** 1113 (28.5) 
Sedentary lifestyle (yes) 246 (18.0) 291 (16.8) 537 (17.3) 
Data were mean ± SD or n (%); Smoking variable has 6 missing value, alcohol drinking has 2 missing 
value, and sedentary lifestyle variable has 814 missing value; the value in men was significantly 
different from that in women at *p<0.05, **p<0.01 by student t test or χ2 test.  
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The baseline characteristics of 3914 study subjects were shown in table 4.1. The mean 
ages of men and women were 54.3 and 53.0 years, respectively. Age, waist 
circumference, waist-to-hip ratio, systolic blood pressure, diastolic blood pressure, 
smoking and alcohol drinking rate were significantly higher in men than those in women, 
while hip circumference, BMI, fasting plasma glucose, plasma cholesterol, HDLC, 
lipoprotein a, Apo A and Apo B were significantly lower in men than those in women. 
Moreover, the proportions of different strata in education level and yearly income were 
also significantly different between men and women by using a Cochran-Mantel-
Haenszel chi-squared test.  
 
4.1.2 Mean glucose concentrations in subgroups 
 
As shown in Table 4.2, fasting plasma glucose concentration increased with age, BMI 
status and yearly income in both sexes. Women had significantly higher glucose level 
than men after 55 years old (p<0.01). And also, overweight women had higher glucose 
level than overweight men. The same difference was observed in low and middle income 
families and in subjects with illiterate and primary education level. 
 
Table 4.2 Mean glucose concentrations in different subgroups in 3914 study subjects 
from Jiangsu Province, China 
 Men Women Total 
N 1748 2166 3914 
Age group (years)    
35-44 5.23±1.64 5.25±1.26 5.24±1.43 
45-54 5.41±1.50 5.52±1.49 5.46±1.50 
55-64 5.54±1.29 5.83±1.91** 5.70±1.67 
65-74 5.68±1.37 5.94±1.93** 5.74±1.69 
BMI status    
Underweight 5.22±0.84 5.44±2.05 5.33±1.54 
Normal 5.42±1.48 5.50±1.62 5.46±1.56 
Overweight 5.47±1.44 5.81±1.72** 5.67±1.63 
Obesity 5.86±1.92 5.84±1.42 5.85±1.60 
Income (RMB Yuan/year)    
Low (<6000) 5.39±1.41 5.51±1.60* 5.46±1.53 
Middle (6000-15000) 5.50±1.55 5.76±1.56** 5.63±1.56 
High (≥15000) 5.56±1.47 6.11±2.87 5.78±2.16 
Education    
Illiterate 5.33±1.06 5.61±1.60** 5.56±1.52 
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Primary school 5.50±1.60 5.76±2.00* 5.63±1.82 
Middle school 5.39±1.41 5.44±1.37 5.41±1.39 
Junior college/university 5.48±1.57 5.40±0.74 5.41±1.44 
* p<0.05, ** p<0.01 tested by student t test. 
4.1.3 Other parameters 
 
Some inflammation, adipocytokines variables was shown in Table 4.3. Women had 
significantly higher leptin level than men (p<0.001). And also, interleukin-6 
concentration was higher in women than in men (p<0.05), while levels of C-reactive 
protein, Von Willebrand factor were lower in women (p<0.05). 
 
Table 4.3 Mean value and standard deviation of other parameters among 269 
subjects by gender 
Variables Men Women P value 
CRP (mg/l) 2.70 (1.70-4.60) 2.50 (1.70-4.30) 0.035 
Leptin (ng/ml) 1406.20 (1015.90) 2561.30 (793.66) <0.001 
Insulin (uIU/ml) 38.70 (18.25) 35.05 (14.03) 0.088 
HOMA-IR 9.41 (5.60) 8.17 (4.71) 0.054 
TPA 11.84 (7.41-25.65) 13.10 (7.94-23.37) 0.771 
TNF-α (pmol/L) 10.74 (8.67) 9.64 (13.31) 0.414 
PAI-1 43.13 (23.68) 46.75 (24.53) 0.238 
Fibrinogen 217.18 (93.20) 206.28 (104.19) 0.391 
IL-6 (pg/ml) 0 (0-0) 0 (0-0) 0.012 
Endothelin-1 (ng/mL) 86.28 (47.80) 78.66 (40.75) 0.167 
VWF 140.14 (131.35) 107.18 (93.98) 0.030 
Data of normal distribution were presented as mean (standard deviation), tested by student t test; data 
of abnormal distribution were presented as median (interquartile range), tested by Wilcoxon test. 
 
4.2 Prevalence and associated factors for diabetes and IFG 
 
4.2.1 Prevalence of diabetes, IFG and hyperglycemia 
 
The overall prevalence of diabetes was 7.7%. The prevalence became little lower after 
age standardization (6.8%). The diabetes was more common in female than in male 
(p<0.05). The age-standardized prevalence of diabetes was higher in women than in men 
(7.6% vs. 5.9%). 
 
The overall and age-standardized prevalence of IFG was 23.1% and 21.0% respectively. 
It was more common in female than in male (p<0.05). The age-standardized prevalence 
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of IFG was higher in women than in men (22.7% vs. 18.9%). 
 
The overall and age-standardized prevalence of hyperglycemia was 30.7% and 27.8% 
respectively. Like diabetes and IFG, hyperglycemia was more common in female than in 
male as well (p<0.01). The age-standardized prevalence of diabetes was higher in women 
than in men (30.3% vs. 24.8%). 
 
Prevalence of diabetes, IFG and hyperglycemia increased significantly with age, yearly 
income, and BMI status, although IFG and hyperglycemia decreased slightly in high 
yearly income group (Table 4.4). Overall, women at age of 65-74 years or with obesity 
had the highest rate of abnormal glucose level regardless of which type it was (diabetes, 
IFG or hyperglycemia). 
Table 4.4 Prevalence of diabetes, IFG and hyperglycemia in 3914 participants aged 
35-74 years in Jiangsu, China 
 N Diabetes (%) IFG (%) Hyperglycemia (%) 
Total 3914 7.7 23.1 30.7 
Age-Standardized 3914 6.8 21.0 27.8 
Sex     
Male 1748 6.6* 21.4* 28.0** 
Age-Standardized, male 1748 5.9 18.9 24.8 
Female 2166 8.6 24.4 33.0 
Age-Standardized, female 2166 7.6 22.7 30.3 
Age group (years)     
35-44 1012 4.1** 15.4** 19.5** 
45-54 1074 7.0 20.6 27.6 
55-64 1097 9.6 28.6 38.2 
65-74 731 10.9 28.9 39.8 
Area     
Urban 762 7.1 26.1* 33.2 
Rural 3152 7.8 22.3 30.1 
Income     
Low (<6000) 2581 7.1* 21.2** 28.3** 
Middle (6000-15000) 1121 8.5 27.1 35.6 
High (≥15000) 212 10.4 24.5 34.9 
BMI status     
Underweight 209 4.3** 18.2** 22.5** 
Normal 2551 7.1 21.0 28.1 
Overweight 1002 9.1 28.0 37.1 
Obesity 152 12.5 31.6 44.1 
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Age-adjusted by direct standardization using the 2000 Chinese census population; Hyperglycemia= 
diabetes+ IFG; * p<0.05, ** p<0.01, by using χ2 test between two categories, or χ2 test for trend 
among all categories. 
 
4.2.2 Risk factors for diabetes 
 
To identify the associated factors of diabetes, univariate and multivariate logistic 
regression were used. Sex, age, yearly income, education level, BMI status, smoking and 
family history of diabetes were showed to be significant predictors for the occurrence of 
diabetes in univariate analysis (Table 4.5).  
Table 4.5 Multivariate regression models for the relationship between diabetes and 
selected sociodemographic, behavioral variables in 3860 participants aged 35-74 
years from Jiangsu, China 
 OR (95% CI)1 p OR (95% CI)2 p 
Sex     
Men 1.00 (referent)  1.00  
Women 1.33 (1.05–1.70) 0.019 1.34 (0.93–1.94) 0.120 
Age group (years)     
35-44 1.00  1.00  
45-54 1.78 (1.20–2.63) 0.003 1.90 (1.27–2.84) 0.002 
55-64 2.51 (1.73–3.64) <0.001 2.53 (1.70–3.75) <0.001 
65-74 2.91 (1.97–4.30) <0.001 3.34 (2.17–5.13) <0.001 
Area     
Rural  1.00  1.00  
Urban 0.90 (0.66–1.22) 0.486 0.69 (0.48–1.00) 0.047 
Income     
Low (<6000) 1.00  1.00  
Middle (6000-15000) 1.21 (0.93-1.56) 0.155 1.27 (0.95-1.69) 0.104 
High (≥15000) 1.51 (0.95-2.40) 0.084 1.86 (1.13-3.01) 0.015 
Education     
<middle school 1.00  1.00  
≥Middle school 0.69 (0.54-0.89) 0.004 0.90 (0.65-1.24) 0.512 
BMI status     
Underweight 0.59 (0.30-1.16) 0.126 0.57 (0.28-1.13) 0.108 
Normal 1.00  1.00  
Overweight 1.30 (1.00-1.69) 0.050 1.18 (0.90-1.56) 0.229 
Obesity 1.86 (1.12-3.08) 0.016 1.71 (1.02-2.89) 0.044 
Smoking     
Never  1.00  1.00  
Former 1.29 (0.72-2.33) 0.396 1.33 (0.68-2.59) 0.403 
Current 0.73 (0.55-0.96) 0.025 0.86 (0.59-1.27) 0.459 
Alcohol drinking     
Never  1.00  1.00  
Former 1.01 (0.43-2.34) 0.990 0.96 (0.39-2.36) 0.928 
Current 0.86 (0.65-1.14) 0.290 1.12 (0.79-1.58) 0.525 
Family history of diabetes     
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No 1.00  1.00  
Yes 3.84 (2.67-5.51) <0.001 4.39 (2.99-6.46) <0.001 
Family history of hypertension     
No 1.00  1.00  
Yes 1.06 (0.82-1.37) 0.643 0.90 (0.69-1.18) 0.447 
1 crude odds ratio, 2 adjusted odds ratio for sex, age, area, yearly income, education, BMI status, 
smoking, alcohol drinking, family history of diabetes, and family history of hypertension. 
OR (odds ratio), 95% CI (95% confidence interval) 
Physical activity: exercise everyday or sedentary<8h. 
 
Age, yearly income, BMI status and family history of diabetes remained significant after 
adjusted for a number of possible confounding variables in multivariate analysis. For 
example, the risk for developing diabetes was almost 3.3 times higher above in the age of 
65 years compared to the younger age group 35-44 years. Family history of diabetes was 
the prime predictor of diabetes in the study population. Person with family history of 
diabetes was 3-6.5 times more likely to have diabetes than one without the history. 
 
However, BMI was found as the strongest modifiable factor for the development of 
diabetes. Overweight and obesity were important risk factors for diabetes, while 
underweight as negatively associated with diabetes independent of sex, age, yearly 
income and other risk factors in the study population. Obese people had almost two times 
higher risk for development of diabetes than people with normal weight. 
 
4.3 Prevalence and determinants for metabolic syndrome 
 
4.3.1 Prevalence and distribution of MetS components 
 
Table 4.6 showed the prevalence of MetS components defined by modified ATP III 
definitions. High blood pressure was the most prevalent components of MetS (45.2%), 
followed by elevated TG (40.1%) and low HDLC (40.1%) in middle-aged and elderly 
Chinese in Jiangsu province. 
 
Table 4.6 Prevalence of MetS components defined by modified ATP III definition, in 
3914 people aged 35-74 years 









Total 3914 33.2 40.1 40.1 45.2 30.7 
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Sex       
Male 1748 17.9 36.9 29.1 49.1 28.0 
Female 2166 45.5 42.7 49.0 42.0 32.9 
Age group (years)       
35-44 1012 30.3 35.7 48.4 28.2 19.5 
45-54 1074 31.3 35.4 43.0 37.5 27.6 
55-64 1097 36.7 44.9 36.0 56.4 38.2 
65-74 731 34.8 45.8 30.6 63.1 39.7 
Area       
Urban 762 34.0 36.2 68.9 40.2 33.2 
Rural 3152 33.0 41.0 33.2 46.4 30.1 
Income       
Low (<6000) 2581 32.4 37.1 39.6 45.1 28.2 
Middle (6000-15000) 1121 35.6 45.1 42.5 44.8 35.6 
High (≥15000) 212 30.2 49.5 34.9 48.6 34.9 
BMI status       
Normal 2551 15.9 32.9 36.2 39.1 28.1 
Overweight 1002 74.3 59.7 50.6 60.0 37.1 
Obesity 152 96.7 63.8 55.3 77.0 44.1 
 
The prevalence of all MetS components except increased blood pressure was higher in 
women in the study population. Prevalence of all MetS components unanimously 
increased with BMI status (Table 4.4 and Figure 4.1). 
 
Figure 4.1 Prevalence of MetS components by different level of BMI in 3914 adults 
 























According to WHO standard, there were 1002 overweight subjects and 152 obese 
subjects in the 3914 individuals of the study sample. The prevalence of overweight, 
obesity, and overweight together with obesity was 25.6%, 3.9% and 29.5% all together 
(Table 4.7). They were more popular in women and in urban area (p<0.01). People 
having higher family income also had higher rates. 
 
Table 4.7 Prevalence of overweight and obesity defined by BMI, among 3914 people 
aged 35-74 years in different subgroups 
 N Overweight (%) 
Obesity 
(%) 
Overweight + Obesity 
(%) 
Total 3914 25.6 3.9 29.5 
Sex     
Male 1748     22.4**    2.9**     25.3** 
Female 2166 28.2 4.7 32.9 
Age group (years)     
35-44 1012 27.1 4.6 31.7 
45-54 1074 23.9 3.3 27.2 
55-64 1097 27.5 3.6 31.1 
65-74 731 23.1 4.2 27.4 
Area     
Urban 762     30.7**     4.7**     35.4** 
Rural 3152 24.4 3.7 28.1 
Income     
Low (<6000) 2581     22.9**   3.4*     26.2** 
Middle (6000-15000) 1121 31.1 4.9 36.0 
High (≥15000) 212 29.7 4.7 34.4 
* p<0.05, ** p<0.01, by using χ2 test between male/female or urban/rural group, or χ2 test for trend 
among all categories. 
 
4.3.3 Prevalence of metabolic syndrome 
 
The overall and adjusted overall prevalence of metabolic syndrome defined by WHO 
criteria was 14.1% and 12.3%, respectively (data not shown). The metabolic syndrome 
was more common in female than in male (χ2=22.8, p<0.001). The adjusted prevalence 
of metabolic syndrome was also higher in women than in men (14.5% vs. 9.7%, p<0.001). 
 
As presented in Table 4.8, the overall prevalence of metabolic syndrome defined by IDF 
criteria was 23.1%. The prevalence became little lower after age standardization (21.8%). 
It was more common in female than in male (p<0.01). The adjusted prevalence of 
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metabolic syndrome was higher in women than in men (27.9% vs. 13.8%). 
 
The overall prevalence of metabolic syndrome defined by modified ATP III criteria was 
31.5%. The standardized prevalence was 30.5%. The metabolic syndrome was more 
common in female than in male (p<0.01). The adjusted prevalence of metabolic 
syndrome was higher in women than in men (34.2% vs. 24.0%). 
 
Table 4.8 Prevalence of MetS in 3914 study subjects from Jiangsu Province by the 
IDF and modified ATP III definitions, respectively  
 n Prevalence a %(95% CI) Prevalence b %(95% CI) 
Overall 3914 23.1 (21.7-24.4) 31.5 (30.1-33.0) 
Overall adjusted*  21.8 30.5 
Male 1748 12.9 (11.4-14.5) † 23.5 (21.5-25.5) † 
Male adjusted*  13.8† 24.0† 
Age group (years)    
35-44 418 16.5 (13.0-20.1) ‡ 25.6 (21.4-29.8) 
45-54 473 12.7 (9.7-15.7) 23.5 (19.7-27.3) 
55-64 494 11.3 (8.5-14.1) 22.7 (19.0-26.4) 
65-74 363 11.3 (8.0-14.6) 22.3 (18.0-26.6) 
BMI status    
Normal 1196 2.6 (1.7-3.5) § 13.0 (11.1-15.0) § 
Overweight 391 38.9 (34.0-43.7) 52.9 (48.0-57.9) 
Obesity 51 82.4 (71.9-92.8) 82.4 (71.9-92.8) 
Female 2166 31.2 (29.3-33.2) 38.0 (36.0-40.0) 
Female adjusted*  27.9 34.2 
Age group (years)    
35-44 594 18.4 (15.2-21.5) § 22.9 (19.5-26.3) § 
45-54 601 24.6 (21.2-28.1) 31.1 (27.4-34.8) 
55-64 603 42.1 (38.2-46.1) 50.1 (46.1-54.1) 
65-74 378 44.8 (39.8-49.9) 53.8 (48.7-58.9) 
BMI status    
Normal 1355 15.7 (13.7-17.6) § 25.2 (22.9-27.5) § 
Overweight 611 62.5 (58.7-66.4) 64.7 (60.9-68.4) 
Obesity 101 80.2 (72.4-88.0) 80.2 (72.4-88.0) 
a prevalence by IDF definition, b prevalence by modified ATP III definition. 
* Adjusted by direct standardization to the gender and age distribution (categorized as 35-44, 45-54, 
55-64, 65-74 years) of the 2000 Chinese census population. 
† p<0.01, χ2 test between male versus female group.  
‡ p<0.05, χ2 test for trend among different age groups. 
§ p<0.01, χ2 test for trend among different age groups or BMI status. 
CI=confidence interval; BMI=body mass index. 
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The prevalence of MetS significantly increased with age in female group independent of 
definitions. And also, the prevalence of MetS significantly increased with BMI status for 
both sexes and both definitions, which was shown in Table 4.8. 
 
 
Figure 4.2 Prevalence of MetS in different sex and age groups (5 years interval) in 
3914 study subjects from Jiangsu Province 
 
Association between prevalence of MetS and age was displayed in Figure 4.2. The 
prevalence of MetS significantly increased with age (5 years interval) in female group by 
both definitions (p for trend<0.001). Additionally, female in the age of 65-69 years had 
the highest rate of metabolic syndrome (Figure 4.2). 
 
4.3.4 Combination type of MetS components 
 
Because metabolic syndrome was a cluster of various factors, which kind of congregation 
was popular deserved discussion in a given population. All of the 5 components and their 
categorizations were identical in IDF and modified ATP III criteria. As shown in Table 
4.9, the most common combination of 3 out of 5 MetS components in the sample of 3914 
subjects was central obesity + high TG + low HDLC, followed by high TG + low HDLC 
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Table 4.9 Combination type of 3 out of 5 MetS components in the sample of 3914 
subjects 
Combination type Frequency Percent (%) 
1, 2, 3 112 2.86 
1, 2 ,4 93 2.38 
1, 2, 5 50 1.28 
1, 3, 4 93 2.38 
1, 3, 5 21 0.54 
1, 4, 5 51 1.30 
2, 3, 4 110 2.81 
2, 3, 5 49 1.25 
2, 4, 5 91 2.32 
3, 4, 5 32 0.82 
In this table, 1 represented central obesity. 2, 3, 4, 5 represented high TG, low HDLC, high blood 
pressure and high FPG, respectively. 
 
The most common combination of 4 out of 5 MetS components in the sample of 3914 
subjects was central obesity + high TG + high blood pressure+ high FPG (136, 3.47%), 
followed by central obesity + high TG + low HDLC + high blood pressure (129, 3.30%) 
(data not shown). 
 
There were 121 persons (28 males, 93 females, 3.09% overall) in the study population 
who had all the five MetS components with them (data not shown). 
 
4.3.5 Determinants of metabolic syndrome 
 
13 potential associated factors for metabolic syndrome were classified and given with 
corresponding value, except age and BMI which were regarded as continuous variable. 
Age and BMI changed per unit of standard deviation. Detailed information was shown in 
Table 4.10. 
Table 4.10 Value assignment for potential associated factors  
Variable Classification and value  
Sex  male=1, female=2 
Age  per 10.9 years 
Area rural=0, urban=1 
Education level <middle school=0, ≥Middle school=1 
Yearly income low (<6000)=1, middle (6000-15000)=2, 
high (≥15000)=3 
 41
BMI per 3.4 kg/m2 
Family history of hypertension no=0, yes=1 
Family history of diabetes no=0, yes=1 
Smoking status no=0, current smoking=1, ever smoking=2 
Second-hand smoking no=0, yes=1 
Alcohol drinking no=0, current drinking=1, ever drinking =2  
Tea consumption ≥1 cup of tea everyday=1, no=0 
Sedentary lifestyle exercise everyday or sedentary<8h=0, 
otherwise=1 
 
All the variables in Table 4.10 were considered in multivariate logistic regression 
(selection=stepwise, sle=0.1, sls=0.1). Only significant factors (p<0.05) by multivariate 
logistic regression analysis were shown in Table 4.11 and Table 4.12.  
 
Gender was found to be significant risk factors for metabolic syndrome independent of 
definition in total analysis including both men and women (OR=1.44, p=0.002). 
 
In men (Table 4.11), BMI status was found to be significant risk factor for metabolic 
syndrome independent of definition. Especially, the risk of having metabolic syndrome 
defined by IDF was 8.3 times as BMI increased per unit of 3.4 kg/m2. Age and family 
history of diabetes were risk factors for metabolic syndrome defined by WHO and 
modified ATP III criteria. And also, smoking was identified as risk factors for metabolic 
syndrome defined by WHO and IDF criteria. Sedentary lifestyle was regarded as risk 
factors for metabolic syndrome defined by IDF and modified ATP III criteria. 
 
Habit of tea consumption for modified ATP III MetS was found as protective factor in 
men. 
 
Moreover, higher yearly income for WHO MetS, living in urban area, family history of 
hypertension for modified ATP III MetS were also identified as risk factors respectively 





Table 4.11 Odds ratio for association between sociodemographic and lifestyle 
variables and metabolic syndrome by multivariate logistic regression in 1316 men 
Significant variable Adjusted OR* (95% CI) p 
MetS a   
Age (per 10.9 years) 1.56 (1.31-1.86) <0.001 
Yearly income 1.31 (1.02-1.66) 0.032 
BMI (per 3.4 kg/m2) 1.50 (1.28-1.76) <0.001 
Family history of diabetes 2.88 (1.61-5.14) <0.001 
Smoking status 1.34 (1.02-1.76) 0.035 
MetS b   
Area 1.57 (1.00-2.44) 0.049 
BMI (per 3.4 kg/m2)   8.29 (6.24-10.99) <0.001 
Smoking status 1.47 (1.05-2.05) 0.024 
Sedentary lifestyle 1.79 (1.14-2.82) 0.012 
MetS c   
Age (per 10.9 years) 1.25 (1.08-1.45) 0.004 
Area 2.09 (1.46-2.98) <0.001 
BMI (per 3.4 kg/m2) 3.79 (3.15-4.56) <0.001 
Family history of diabetes 1.89 (1.04-3.44) 0.038 
Family history of hypertension 1.42 (1.00-2.01) 0.049 
Sedentary lifestyle 1.47 (1.02-2.11) 0.038 
Tea consumption 0.70 (0.51-0.96) 0.028 
a prevalence by WHO definition; b prevalence by IDF definition; c prevalence by modified 
ATP III definition. * Adjusted for all the variables in Table 4.10. 
 
In women (Table 4.12), age, BMI status and family history of hypertension were found to 
be significant risk factors for metabolic syndrome independent of definition. Especially, 
the risk of having metabolic syndrome defined by IDF was 6.2 times as BMI increased 
per unit of 3.4 kg/m2. Family history of diabetes was risk factor for metabolic syndrome 
defined by WHO and modified ATP III criteria. And also, smoking was identified as risk 
factors for metabolic syndrome defined by IDF and modified ATP III criteria.  
 
Higher education level was found as protective factor for WHO-definition MetS in 
women. 
 
Moreover, higher yearly income was also identified as risk factor for WHO MetS, the 
same as living in urban area for modified ATP III MetS, in female participants. 
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Table 4.12 Odds ratio for association between sociodemographic and lifestyle 
variables and metabolic syndrome by multivariate logistic regression in 1651 women 
Significant variable Adjusted OR* (95% CI) p 
MetS a   
Age (per 10.9 years) 1.61 (1.38-1.88) <0.001 
Education level 0.67 (0.47-0.94) 0.021 
Yearly income 1.49 (1.18-1.87) <0.001 
BMI (per 3.4 kg/m2) 1.46 (1.29-1.66) <0.001 
Family history of diabetes 1.68 (1.02-2.75) 0.041 
Family history of hypertension 1.46 (1.08-1.98) 0.014 
MetS b   
Age (per 10.9 years) 1.97 (1.70-2.27) <0.001 
BMI (per 3.4 kg/m2) 6.18 (5.10-7.49) <0.001 
Family history of hypertension 1.41 (1.03-1.94) 0.033 
Smoking status 1.81 (1.06-3.10) 0.031 
MetS c   
Age (per 10.9 years) 1.97 (1.73-2.24) <0.001 
Area 1.34 (1.02-1.77) 0.038 
BMI (per 3.4 kg/m2) 3.61 (3.11-4.20) <0.001 
Family history of diabetes 1.66 (1.01-2.72) 0.045 
Family history of hypertension 1.56 (1.16-2.10) 0.003 
Smoking status 2.10 (1.24-3.56) 0.006 
a prevalence by WHO definition; b prevalence by IDF definition; c prevalence by modified 
ATP III definition. * Adjusted for all the variables in Table 4.10. 
 
4.4 Agreement for different definitions of metabolic syndrome 
 
Table 4.13 Agreement between the WHO, IDF and modified ATP III criteria in 
diagnosing metabolic syndrome 
Modified ATP III   
+ - Total Kappa (95% CI) 
+ 416 134 550 
- 818 2546 3364 WHO 
Total 1234 2680 3914 
0.34 (0.31-0.37) 
+ 902 0 902 
- 332 2680 3012 IDF 
Total 1234 2680 3914 
0.79 (0.77-0.81) 
WHO   
+ - Total  
+ 289 613 902 
- 261 2751 3012 IDF 




From table 4.13, substantial agreement (κ=0.79) was found between IDF and modified 
ATP III definitions. They agreed with each other with highest degree among three 
comparisons. All of the positive subjects, who were diagnosed by IDF definition, were 
also modified ATP III definition positive. Fair agreement (κ=0.34) was found between 
WHO and modified ATP III definitions. And also fair agreement (κ=0.27) was observed 
between WHO and IDF definitions, and it was the lowest one. 
 
4.5 Weight gain 
 
Table 4.14 Logistic model relating 10-year BMI change to hyperglycemia, MetS by 3 
definitions, stratified by BMI status 10 years ago among 2343 subjects in Jiangsu 
 Cases OR1 (95% CI) P1 OR2 (95% CI) P2 
Hyperglycemia      
Underweight 20 1.01 (0.82-1.24) 0.951 1.04 (0.83-1.30) 0.731 
Normal 329 1.11 (1.06-1.16) <0.001 1.12 (1.06-1.17) <0.001 
Overweight 129 1.05 (0.97-1.13) 0.184 1.04 (0.96-1.12) 0.367 
Obesity 14 0.84 (0.67-1.04) 0.111 0.88 (0.69-1.13) 0.316 
MetS a      
Underweight 4 1.08 (0.72-1.63) 0.711 1.01 (0.61-1.66) 0.971 
Normal 113 1.12 (1.05-1.20) <0.001 1.16 (1.08-1.25) <0.001 
Overweight 78 1.03 (0.95-1.13) 0.467 1.02 (0.93-1.12) 0.670 
Obesity 8 0.87 (0.68-1.12) 0.285 0.92 (0.67-1.25) 0.579 
MetS b      
Underweight 4 2.69 (1.41-5.12) 0.003 - - 
Normal 273 1.55 (1.46-1.65) <0.001 1.70 (1.58-1.83) <0.001 
Overweight 188 1.39 (1.27-1.52) <0.001 1.44 (1.31-1.59) <0.001 
Obesity 24 1.30 (1.02-1.65) 0.032 1.28 (0.94-1.75) 0.118 
MetS c      
Underweight 15 1.42 (1.12-1.79) 0.004 1.42 (1.08-1.85) 0.011 
Normal 431 1.41 (1.34-1.49) <0.001 1.48 (1.39-1.56) <0.001 
Overweight 222 1.29 (1.19-1.40) <0.001 1.31 (1.21-1.43) <0.001 
Obesity 25 1.26 (1.00-1.59) 0.051 1.24 (0.93-1.65) 0.140 
a prevalence by WHO definition; b prevalence by IDF definition; c prevalence by modified ATP III 
definition. Hyperglycemia=IFG + diabetes; 1 crude odds ratio and p value; 2 odds ratio and p value 
adjusted for sex, age, area, yearly income, education, smoking, alcohol drinking, family history of 
diabetes.1 unit change in BMI was 2.9 kg for a 1.7-m-tall person. 
 
Additional analysis on Association between 10-year weight gain and the risk of 
hyperglycemia and metabolic syndrome by 3 definitions was shown in Table 4.14. Due to 
the number of observations in each stratum, hyperglycemia instead of diabetes was 
considered here. Weight gain was calculated as the difference between weight at survey 
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and weight ten years ago. In consideration of different height of subjects, it was change 
into 10-year BMI change in the model.  
 
Table 4.14 further indicated weight gain was particularly risk factor for each disease 
among originally normal weight population (p<0.001). For person with normal weight 10 
years ago, if BMI increase 1 unit, the risk of developing MetS by IDF definition would 
have a 1.7-fold average increase.  
 
4.6 Analysis on nontraditional risk factors 
 
4.6.1 Simple and partial correlation 
 
By simple correlation analysis, fasting glucose level was found positively correlated with 
BMI, waist circumference, triglyceride, HDLC, systolic blood pressure, fructosamin, 
HOMA-IR, interleukin-6 in both sexes. After adjusted for age, area, education, family 
history of diabetes, smoking, drinking, and sedentary lifestyle, these correlations except 
HDLC in male still remained significant. Further adjustment for BMI didn’t weaken the 
relationship between glucose level and triglyceride, HDLC in female, fructosamin, 
HOMA-IR, interleukin-6 (Table 4.15). 
 
Fasting plasma glucose appeared to negatively correlate with fasting insulin in male and 
uric acid for both sexes but was not significant (P>0.05).  
 
In female, not male, glucose level also positively correlated with C-reactive protein, 
plaminogen activator inhibitor-1, Von Willebrand factor, they remained significant after 
adjustment potential confounding factors including BMI. Specially, in female group, 
leptin significantly correlated with glucose, after adjustment this relationship became 






Table 4.15 Correlation analysis between FPG and other variables in selected 
participants 
Male Female Variable Simple Model 1 Model 2 
 
Simple Model 1 Model 2 
BMI 0.071** 0.077** —  0.096*** 0.070** — 
WC 0.086*** 0.082** 0.034  0.122*** 0.076** 0.034 
TG 0.234*** 0.235*** 0.223***  0.250*** 0.226*** 0.220*** 
HDLC 0.064** 0.027 0.055  0.112*** 0.085*** 0.103*** 
SBP 0.066** 0.025 0.003  0.102*** 0.025 0.000 
DBP 0.049* 0.046 0.021  0.004 -0.019 -0.043 
Fructosamin 0.261*** 0.267*** 0.262***  0.470*** 0.477*** 0.479*** 
Uric acid -0.066 -0.066 -0.080  -0.017 -0.004 -0.005 
Log CRP 0.032 0.034 0.031  0.109*** 0.088** 0.086*** 
Leptin 0.001 0.028 -0.065  0.182* 0.249** 0.283*** 
Insulin -0.067 -0.028 -0.045  0.091 0.094 0.094 
HOMA-IR 0.478*** 0.511*** 0.499***  0.749*** 0.745*** 0.758*** 
PAI-1 0.169 0.125 0.099  0.216*** 0.224** 0.224** 
TPA 0.008 -0.038 -0.041  0.060 0.052 0.059 
TNF-α 0.050 0.108 0.094  -0.041 -0.064 -0.070 
Fibrinogen 0.102 0.079 0.071  -0.078 -0.097 -0.095 
IL-6 0.390*** 0.410*** 0.425***  0.527*** 0.513*** 0.515*** 
FFA 0.096 0.073 0.063  -0.093 -0.115 -0.119 
Endothelin-1 0.106 0.144 0.128  -0.144 -0.166* -0.168* 
VWF 0.181 0.160 0.158  0.260*** 0.213** 0.213** 
FDP 0.037 0.010 0.007  0.042 0.018 0.016 
D-dimer 0.033 0.040 0.031  0.131 0.129 0.125 
In multiple correlation analyses, values in model 1 were adjusted for age, area, education, family 
history of diabetes, smoking, drinking and sedentary lifestyle. Model 2 further adjusted for BMI. 
* P<0.05, ** P<0.01, *** P<0.001 for coefficient. In order to use the data information at the largest 
degree, the number of observations was different when analyzing on MetS components and other 
parameters, n=3910 for analysis on BMI, WC, TG, HDLC, SBP and DBP; n=914 for fructosamin and 
uric acid; n=2323 for Log CRP; n=269 for all other parameters. 
 
4.6.2 Further analysis on fructosamin and HOMA-IR 
 
Fructosamin and HOMA-IR were selected for further analysis. Table 4.16 showed 
adjusted odds ratios from multivariate logistic regression. After controlled possible 
confounders, both parameters were associated with increased risk of developing diabetes. 
Table 4.16 Associations between diabetes and fructosamin, HOMA-IR 
 Odds ratio* 95% CI P 
Fructosamin (n=906) 1.37 1.24-1.51 <0.001 
HOMA-IR (n=266) 1.29 1.15-1.45 <0.001 
* Odds ratios were adjusted for age, sex, BMI, area, education, family history of diabetes, smoking, 




5.1 Discussion of main findings 
 
5.1.1 Prevalence of diabetes 
 
In general, 7.7% and 21.0% of adults aged 35-74 years were observed with diabetes and 
IFG in Jiangsu province in the present study, which was much higher than any of the 
previous large-scale diabetes studies in China(17-19). In the study named InterASIA(19), 
conducted in 2000-2001 including a large representative sample of Chinese adult 
population with the totally same age span, the prevalence of diabetes and IFG were 5.5% 
and 7.3%, respectively. Our study was conducted in the year of 2002 around, however, it 
indicated a much higher rate compared to InterASIA study. The prevalence of diabetes in 
all of the groups was higher than that in InterASIA. Especially, marked increase in the 
proportion of people with IFG was found, which have been identified as risk factor for 
overt diabetes and cardiovascular disease(82), although there were two possible 
explanations for the difference. Firstly, diagnostic criteria for IFG used in our study were 
lower than InterASIA (5.6–6.9 mmol/l vs. 6.1–6.9 mmol/l). Secondly, as demonstrated 
above, Jiangsu province is one of the most developed areas in China. Its higher rate of 
diabetes than nationwide studies also possibly due to different population sampling 
results. 
 
The latest large-scale study in China was the 2002 China National Nutrition and Health 
Survey (NNAHS), which had national representative sample from 31 provinces, 
autonomous regions, and municipalities. The prevalence of diabetes was 2.6% in Chinese 
adults aged 18 and over, but it reached into 4.3% and 6.8% in people aged ≥45 years and 
≥60 years, respectively. And also, the prevalence of IFG was 1.9% in Chinese adults aged 
18 and over, it increased into 3.4% and 4.9% in people aged ≥45 years and ≥60 years, 
respectively. The prevalence of diabetes and IFG increased with age, with higher 
increasing speed found in large city(103). Our study was conducted almost at the same 
time with NNAHS, but the corresponding results in the population with same age in our 
study were higher than this report. Except IFG criteria used in our study were lower (5.6–
6.9 mmol/l vs. 6.1–6.9 mmol/l) which could explain part of difference in the IFG rate, 
 48
however, it still indicated the situation of diabetes and IFG was more serious than the 
average level of the country.  
 
In contrast, estimated prevalence of diabetes in our sample is lower than that in some 
developed countries during the same period(13, 104, 105). For example, the US National 
Health and Nutrition Examination Surveys of 1999–2002(13) showed the adjusted 
prevalence of diabetes was 9.8%, using the same diagnostic criteria with our study. 
Results from the Diabetes Heart and Health Survey (DHAH)(105) carried out in 
Auckland, New Zealand in 2002-2003 reported the adjusted prevalence of diabetes was 
9.3% all together. 
 
The prevalence of diabetes increased with age and BMI status of both sexes in the present 
study, which was supported by many other studies throughout the world(13, 18, 19). And 
also, in accordance with the findings by Pan et al (18), it was higher in female and in 
better income family, which was also similar with other studies. 
 
Our study has public health significance. It indicated that a large number of adults in 
Jiangsu province have diabetes or impaired fasting glucose because of large total 
population. Prevention and treatment of diabetes and its various complications, and 
reduction of risks of other chronic diseases should be urgently put on the agenda. 
 
5.1.2 Prevalence of metabolic syndrome 
 
The findings in our survey estimated that 12.3%, 21.8% and 30.5% adults aged 35-74 
years living in Jiangsu were affected with metabolic syndrome applying to WHO, IDF 
and modified ATP III criteria. It can be easily found that the rate is increasing remarkably 
when comparing it with the results from the study in 1992, which indicated the 
prevalence of the syndrome was 13.3% using their own criteria referred to WHO, ATP III 
definitions(45). The adjusted prevalence was even higher than the results from another 
study also conducted in Jiangsu province in 2006(48) using the same definition (IDF 
criteria used). It can be explained in two ways. First, the population sampled was 
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different. The proportion of south areas in our study was higher than that study. The 
second, the age of subjects in our study was older than that study (people in 35 years old 
as youngest compared to 20 years old). So, these two differences may have concealed the 
increasing trend of metabolic syndrome. Other than the overall prevalence, the same 
conclusions were still drawn that the prevalence was higher in female and the elderly. 
 
The metabolic syndrome was more common in female than in male independent of 
definitions in the current study, which was supported by other studies in China(48, 49). It 
was inconsistent to the study in Japan(41) which showed a higher rate in female, this 
mainly due to the latter study used a larger waist circumference cut-off value for females 
(90 cm) than for males (85 cm) based on the Japanese diagnostic criteria. 
 
An interesting finding is the opposite age trend between genders when IDF criteria was 
applied. In female, the prevalence of metabolic syndrome increased with age. But in male, 
the prevalence decreased with the age. This was possibly due to prevalence of MetS 
components like central obesity (waist circumference) and low HDLC decreased with age 
in male. Similar report on inverse association between MetS and age in men can not be 
found so far. However, one study from China reported age was negatively associated with 
obesity in middle-aged and elderly people(106). Such a negative association between 
MetS and age in men may be due to effect of androgen levels on adipose distribution and 
metabolism. And also, westernized lifestyle characterized by a combination of excessive 
energy intake and inadequate physical activity may have less effect on old men compared 
to youngsters. Old men are likely to prefer traditional Chinese food and exercise more 
frequently, while young men may possibly consume more westernized food and spend 
the majority of time staying in office and at home. 
 
5.1.3 Overweight and obesity 
 
It has been clear from a large number of epidemiological studies that overweight and 
obesity were important modifiable risk factors for various chronic diseases like 
cardiovascular disease and diabetes(8). In the present study, BMI status was further 
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confirmed as the strongest modifiable factor for the development of diabetes. And also, 
BMI status was also proved to be significant risk factors for metabolic syndrome 
independent of definitions. 
 
Overweight and obesity has been increasing in most parts of the world for several 
decades, so has in China(107). The epidemics of diabetes and obesity have reached a 
crisis level(108). The prevalence of overweight and obesity increased by 40.7% and 
97.2%, respectively, among adults in China from 1992 to 2002(107). In our study, the 
prevalence of overweight, obesity, and overweight together with obesity was 25.6%, 
3.9% and 29.5% all together according to WHO classification(102). The prevalence is 
higher in women and in urban area. It was in line with other study conducted in 2000-
2001 in China(109).  
 
Result from our study indicated that weight gain was particular risk factors for 
hyperglycemia and metabolic syndrome among originally normal weight population. 
Therefore, control of body weight is of great importance to the prevention and treatment 
of related chronic diseases like diabetes, hypertension and metabolic syndrome. 
Excessive caloric intake from fast food, insufficient exercise, increased reliance on 
automobiles, popularization of television, and so on all result in weight gain(108). 
Therefore, prevention strategy should be clearly targeting on these issues. 
 
5.1.4 Non-modifiable risk factors 
 
Effects of age, gender and family history of diabetes on diabetes and metabolic syndrome 
were analyzed in our study. Age and family history of diabetes were significant risk 
factors for diabetes after adjusted for confounders while sex lost its significance after the 
adjustment. However, women had significantly higher prevalence of diabetes than men in 




Gender difference, trend with age, and association between family history of diabetes and 
chronic disease like diabetes were well established and repeatedly supported by a great 
deal of studies. But also, gender difference had impact on diabetes as risk of other 
diseases like coronary heart disease(110). 
 
Although these risk factors cannot be changed, prevention and intervention measurements 
should be focused on this population with these characteristics. That is to say, women, 
old people and people with family history of diabetes should be the emphasis population 
of prevention and control. In addition, it will be more cost-effective to screen such 
persons before modifiable risk factors in these persons were designed to be changed. 
 
5.1.5 Modifiable risk factors 
 
Sedentary lifestyle was identified as risk factors for metabolic syndrome defined by IDF 
standard in our study sample (adjusted OR=1.37, p<0.05). As described above, physical 
inactivity has been found, in both cross-sectional and longitudinal studies, to be an 
independent predictor of Type 2 diabetes(54). Appropriate frequency and intensity of 
exercise undoubtedly should be recommended as a prevention and treatment for Type 2 
diabetes, metabolic syndrome, and some other chronic diseases.  
 
Dietary factors were not analyzed in the current study. However, in many intervention 
studies, dietary factors were elucidated to play an important role and dietary modification 
was cornerstone of prevention and management of Type 2 diabetes and metabolic 
syndrome(57, 58). 
 
Smoking was identified as risk factors for metabolic syndrome defined by WHO and IDF 
criteria in men and it was also increase the risk of metabolic syndrome defined by IDF 
and modified ATP III criteria in women. Although alcohol drinking was not identified as 
significant risk factors in our study. However, these two factors especially smoking were 
also found associated with an increased risk of type 2 diabetes(111) and metabolic 
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syndrome(112, 113) in many studies. Consequently, smoking cessation and limitation of 
alcohol consumption should be implemented in public health practice all the time. 
 
In addition, an interesting finding in our study was that habitual tea drinking was found as 
protective factor for metabolic syndrome defined by modified ATP III criteria in men. To 
our knowledge, no study has reported this association. In a Japanese study, the 
researchers didn’t find the inverse association between green tea consumption and 
metabolic syndrome(114). However, accumulating evidence indicates that consumption 
of tea, especially green tea, has potential protective effect on the prevention of many 
diseases especially cancer(115). Consumption of green tea was also inversely associated 
with risk for diabetes, which was reported in Japan(116). In animal experiment, whole 
teas significantly reduced abdominal white adipose tissue both in female and male 
mice(117), while abdominal obesity is exactly one of the MetS components. However, its 
protective effect still needs to be further verified in follow-up studies before a 
recommendation is given. 
 
5.1.6 Agreement and applicability of different definitions 
 
Due to lake of uniform definition for MetS, a number of studies, most of them were 
cross-sectional ones, tried to compare and evaluate currently available definitions. The 
prevalence of MetS differed from each other when different criteria were used in same 
research population. Even 5-fold difference in the prevalence was found(118). And also, 
remarkable differences in the biochemical and clinical profile of positive subjects 
diagnosed by different criteria were observed(118). The highest overall agreement was 
observed between IDF and modified ATPIII definition which was similar in different 
studies(119-122), which was also in accordance with our study (κ=0.79, highest in three 
comparisons). Validity of the definitions were also discussed and suggestions for 
modification were given in Italian(123),Korean(124), Japanese(125) population. 
However, there were also no consistent opinions on the validity or applicability of 
various definitions. In few prospective studies, risk predictive ability by different 
definitions were also compared like in USA(71).  
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Other than the comparison, in some countries, researchers also set specific diagnostic 
criteria suitable for specific population in their countries. For instance, Chinese Diabetes 
Society (CDS) put forward a suggestion of MetS diagnostic criterion based on research 
results on the disease in Chinese population in 2004(126). A committee of Japanese 
specialists also established a diagnostic criterion of Japan-specific MetS in 2005(127).  
 
5.1.7 Weight gain 
 
Results from our study showed that WHO and IDF criteria of MetS neglected 80% cases 
of hyperglycemia in originally underweight person, while modified ATP III criteria can 
detect more similar number of cases in the population. From this perspective, it indicates 
that ATP III criterion is more powerful than the other two definitions in Chinese adults 
from our study. 
 
Results from our study indicated 10-year weight gain was particularly risk factor for 
diabetes and metabolic syndrome among originally normal weight population (p<0.001). 
It was also risk factor in some other BMI group, but the results were not consistent. It is 
possibly caused by a small number of participants in those categories. Another possible 
reason is lean people was originally prone to be malnutrition and weight gain made them 
nearer to normal standard, while the majority of obese people had already suffered from 
the disease 10 years ago. 
 
Study conducted in Japan(56) indicated weight gain increased the risk of Type 2 diabetes 
even in relatively lean people. Although the conclusion were not confirmed, avoidance of 
weight gain, weight loss in overweight and obese people is important to reduce the risk of 
the disease. 
 
Another different issue needs to be aware is called “insulin-induced weight gain”, which 
was found in the treatment of diabetes with insulin(128, 129). Study from UK(130) 
showed those who received insulin treatment gained, on average, 5 kg from the start of 
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the study. The coping strategies include limiting dose by increasing insulin sensitivity 
through diet and exercise (first-line treatments), insulin replacement regimens, etc(128).  
 
5.1.8 Inflammation factors 
 
In the present study, fasting glucose level was found positively correlated with 
interleukin-6, in both sexes adjusted for a number of confounding factors. Interleukin-6 is 
a cytokine that has abroad range of humoral and cellular effects, and elevated plasma 
interleukin-6 was associated with type 2 diabetes(131), which supports our results. And 
also, glucose level positively correlated with leptin, C-reactive protein, plaminogen 
activator inhibitor-1, Von Willebrand factor in female subjects in our study. 
 
As reported by many epidemiological studies, biomarkers of low-grade systemic 
inflammation like C-reactive protein, plaminogen activator inhibitor-1, fibrinogen, Von 
Willebrand factor, leptin and other various adipocytokines were evaluated to be 
associated with diabetes and metabolic syndrome. For instance, leptin concentration was 
strongly correlated wit percentage body fat(132). High leptin levels, probably reflecting 
leptin resistance, predict an increased risk of diabetes. However, a protective association 
between leptin and diabetes was found after adjusting for factors related to leptin 
resistance(133). C-reactive protein (CRP) was considered as an important predictor of 




In general, the present study has mainly three implications.  
 
One, this study would contribute to secondary and tertiary prevention in the province. 
Some participants were diagnosed and could also be treated in an early stage. Subjects 
with positive results would attach more importance to the treatment and management of 
diseases, so would their family. And also, a high proportion and large number of people 
were found with or at risk of diabetes and metabolic syndrome in Jiangsu province, which 
require being paid more attention. 
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The second, some associated factors were identified in the present study, which could 
serve as basis of prevention. In conjunction with other literatures, active prevention 
campaign can be done in the whole population aiming at altering modifiable risk factors 
and with emphasis on population with non-modifiable risk factors. It can also enhance 
people’s concern of prevention and control and decrease the possibility of disease 
occurrence. Moreover, associated factors identified in our study may be similar in other 
Chinese population such as people living in other parts of the country, or Chinese 
overseas immigrants. Therefore, similar intervention and prevention suggestions can be 
put forward with certain cautions. 
 
The third, prevention approaches and suggestions were proposed in our study to address 
these problems. As illuminated in the beginning, prevention is the most cost-effective 
method to deal with these problems. And also, it is the only feasible approach to help 
reverse the negative trends in the incidence of diseases. 
 
5.3 Methodological discussion 
 
5.3.1 The strength of the study 
 
In general, the main strength of the current study lies in the quality control of 
anthropometric and blood parameters.  
 
Anthropometric parameters like height, weight, waist circumference were measured by 
well-trained investigator, which made them more reliable than self-reported results. And 
also, health investigators were asked to take measurement as accurate as possible, and the 
mean value of three measurements was used for analysis.  
 
Blood samples were collected in 3 different tubes for each participant by experienced 
professionals. Aside from samples in EDTA tube, all samples in non-anticoagulant and 
fluoride tubes were centrifuged in local health service center within 3 hours to separate 
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plasma. All samples were then refrigerated and stored at -20 ºC until laboratory assays 
could be done.  
 
Blood specimen under cryopreservation were then packed and marked with type and code, 
attached with necessary explanation document. All of them were transported with cold 
chain to central laboratory in Provincial CDC. 
 
Blood variables like FPG and lipid profile were measured by enzymology method using 
automatic biochemical analyzer. Clinical sensitivity and specificity for the selection of 
enzymology method were considered. Reference serum was used for internal quality 
control everyday. 
 
On the other hand, large sample size made it possible that the calculation of prevalence 
estimates and risk factors analysis. As describes in methodology part, the final sample 
size in the survey was 3914, which was larger than any one of theoretical values 
according to either diabetes or metabolic syndrome and could meet the requirement of 
analysis. 
 
In addition, most potential confounders like gender, age, family history, etc. were 
carefully controlled. For example, stratification controlled effectively between-stratum 
confounding, standardization and multivariate analyses such as logistic regression, partial 
correlation were used to control the confounding.  
 
5.3.2 The limitations of the study 
 
Some limitations should however be pointed out in the present study.  
 
Cross-sectional nature This is the major limitation of our study, which limits causal 
inference between exposure and disease since data on temporal sequence is lacking, 
although a cross-sectional study will preferentially identify chronic diseases because 




Selection bias Bias can be usefully defined as s systematic deviation from the truth, 
which has potential impact on the quality of data(134). Cluster sampling method was 
used in our study. It has disadvantage of lower accuracy due to higher sampling error. 
Although integrated with stratified sampling, the sample in our study may not be 
representative for the area. There are several reasons for this. Firstly, because the main 
task of the project is follow-up of participants instead of prevalence estimation, 
compliance of subjects was the emphasis of consideration, and this is the main reason. So, 
although the sampling method was designed ideally, there was some inconsistency in 
practice. As a result, the sample size in urban area is relatively small while large in rural 
areas. It possibly underestimated the prevalence of disease due to possibly higher rate in 
urban area. Secondly, only 4 communities/villages in study area can not represent the 
whole province because the socioeconomic disparities exist from place to place. Thirdly, 
there was also non-respondent bias and incomplete response in our study. It is possible 
that person with disease were more likely to response than those completely well. Maybe 
subjects with positive health behaviors were more likely to response(134). 
 
As explained above, the findings in the present study may not be representative and 
caution should be taken into account if generalizing to the whole population of Jiangsu 
province, let alone China. There are huge disparities in different areas within the country. 
For example, there are 56 ethnic groups and different demographic characteristics 
between areas. However, it is still a valid sample to compare gender differences and to 
identify associated factors for diabetes and metabolic syndrome in Jiangsu province. 
 
Information bias First, observer bias may exist in our study. For example, diet and 
exercise information collected in different time may be different. Second, subject bias 
may typically take the form of recall bias(134), which mostly happens in case-control 
study. But, in our cross-sectional study, it can also exist. For instance, information about 
body weight 10 years ago and disease history may deviate from the truth. 
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Questionnaire issue Compared to self-reported questionnaire, ideally, interviewer-
administered questionnaire may have several advantages: (a) High response rate. (b) The 
completeness of the answers can be more assured by this approach. (c) The interviewer 
can give guidance and explanations to those complex questions. However, it also has 
some disadvantages: (a) The subjects have to confront the interview which could 
influence their answers. (b) Variability due to differences in the approach used by the 
interviewer and in the interpretation of any replies(134). In our study, the interviewer 
were trained and also given survey guideline to read to ensure presenting material in a 
similar manner. However, it is difficult to exclude the possibility of interaction between 
the subjects and the interviewer(134). (c) The subjects have no time to consider their 
answers and/or change them after an initial response(134). In addition, the questionnaire 
used in our study may be too long for the subjects to endure the whole process and for 
interviewer to check it carefully, which possibly distorted the real information. And also, 
their contact information such as name, address was recorded, which could make some 
sensitive questions like family income imprecise. There were still some missing values 
there. Lastly, the questionnaire used in the survey was not validated.  
 
Finally, regarding the association between some variables, such as 10-year weight gain 
and the metabolic syndrome defined by WHO criteria in the participants who were 
underweight or obese 10 years ago, our results may reflect some problems of statistical 
power, due to the small number of participants in those categories. 
 
5.4 Follow up and intervention suggestions 
 
5.4.1 Follow-up study 
 
Given exposure status when measured will refer to “current status” and this is measured 
prior to disease onset, the issues of temporality of disease/exposure, recall bias will not, 
in general, affect cohort study(134). 
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For example, from this cross-sectional data we didn’t find association between alcohol 
drinking and the diseases. Maybe people had changed their lifestyle like quitting from 
alcohol drinking after suffering from the disease. 
 
For this reason, prospective follow-up study is more powerful methodology to identify 
this kind of issues. Our project is on its way. It will try to find causal relationship between 
metabolic syndrome/components and diabetes. And also, it can validate the prognostic 
power of different definitions of metabolic syndrome. It is the basis for prevention and 
control to establish health strategies in population on the basis of recognition of the 
epidemiological characteristics and its dynamic changes, risk factors, and health effects, 
etc. 
 
5.4.2 Diet and lifestyle modification 
 
It is clear from our study results that the prevalence of diabetes and metabolic syndrome 
is very high compared to other previous studies in China and it is still increasing rapidly 
in Jiangsu province. It can be assumed that a large number of adults in Jiangsu province 
have diabetes, impaired fasting glucose and metabolic syndrome because of large total 
population. Therefore, interventions should be implemented in Jiangsu as soon as 
possible.  
 
Cumulative evidence from the prospective studies consistently showed a reduced risk for 
diet and other lifestyle modification on the development of Type 2 diabetes (57, 82, 84, 
86, 87). And also, they are regarded as the basis in the prevention and management of 
Type 2 diabetes and metabolic syndrome. 
 
Change of dietary factors is one of the most important approaches. Chinese Food Guide 
(2007), proposed by Ministry of Health, is a guideline for healthy diet. For example, 
diversity of food, increase intake of vegetable and fruits, consumption of milk and 
soybean or its products everyday, less oil and salt, exercise everyday and so on. 
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Exercise is the second important approach to deal with the problem. An appropriate 
frequency, intensity and duration of exercise undoubtedly should be recommended as a 
prevention and treatment for Type 2 diabetes, metabolic syndrome, and some other 
chronic diseases.  
 
Control of body weight is of great importance to the prevention and treatment of these 
chronic diseases. And also, appropriate weight can be surrogate of control effect. 
 
Many studies, also supported by the present study, indicated women, old people and 
people with family history of diabetes are at more risk of disease. So, they should be 
given priority in the practice of prevention and control. In addition, it will be more cost-
effective to screen such persons before modifiable risk factors in these persons were 
designed to be changed. However, another important population is children. Special role 
in future society and fact of at more adulthood risk of chronic diseases should make them 
of special concern. 
 
Moreover, smoking cessation and limiting alcohol consumption should be implemented 
in public health practice all the time. 
 
5.4.3 Primary, secondary and tertiary prevention 
 
Regarding the prevention of diabetes and metabolic syndrome, it can be classified into 
three levels: 
 
Primary prevention aims at modification of the risk factors such as unhealthy diet, 
sedentary lifestyle, overweight and obesity, and so on, in high risk populations to reduce 
the occurrence of pre-diabetes and MetS components. Secondary prevention aims to 
prevention the development from pre-diabetes and MetS components to overt diseases. 
Tertiary prevention involves standardized treatment and management of diseases, for 




Extensive prevention and control of disease in the society actually is not a research issue 
any more, but needs the cooperation and effort of many systems including government, 
NGOs, media, and all the people. 
 
Developing a health system where prevention is recognized as the most cost-effective 
intervention is key to the fight against chronic diseases(135). However, In China, nearly 
70% of Government expenditures focus on curative services in hospital and urban areas 
(135). Therefore, the emphasis should move forward to prevention and the range should 
be extended to rural areas where the majority of people live in. Especially in Jiangsu 
province, one of the most developed areas in China, more investment can be made for 




In conclusion, our results indicate a high prevalence of diabetes, impaired fasting glucose 
and metabolic syndrome among middle-aged and elderly adults in Jiangsu province, 
China. We also found some modifiable and non-modifiable factors related to these 
diseases. Considering the tremendous economic and human resource costs, public health 
intervention programs and community-based strategies for lifestyle modification are of 
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Questionnaire on disease history and lifestyle 
 
Investigation date： □□□□ year □□ month □□ day 
Starting time of investigation：□□ hour □□ minute (24 hours system) 
Area code: Suzhou=1     Changshu=2     Ganyu=3    Jintan=4                                    □ 
Name                                      ID number □□□□□ 
        City              town        Street (Village) Family 




Participant’s office tel. □□□□-□□□□□□□□                          
Participant’s home tel./mobile tel. □□□□-□□□□□□□□                      Contact 
information Permanent contact tel.□□□□-□□□□









Has venous blood been drawn for testing? Yes=1   No=2 □ 
Has blood specimen been obtained after fasting? Fasting＝1 Postprandial＝2 Not drawn=3 □ 
 
Investigator ____________________ (Signature) 
Investigation result □   (Finished=1    Not finished=2    Rejected=3)    
Quality controller ____________________ (Signature) 
Quality inspection result  □   (Qualified=1   Not qualified=2)        
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A. General Information 
 1. Name：            
2. Sex：    Male=1    Female=2                                                                                                           □ 
3. Date of birth：(yyyy/mm/dd)                        □□□□/□□/□□ 
  4. Time residing here (years):                                       □□ 
5. Occupation: Brainwork entirely=1  Brainwork mainly=2  Physical work=3  Physical work entirely=4□  
a. What main types of work have you done so far (in order) ①        ②        ③           
 6. Education: Illiterate=1  Primary school=2  Junior high school=3  Senior high school/technical 
secondary school=4  higher than junior college=5                       □ 
 7. Marital status: Single=1 Married=2  Divorced=3  Widowed=4  Separated =5 □ 
 8. How many family members do you have (including yourself)? □□ 
 9. Average family annual income (RMB):                                                                  □□□□□□ 
10. How many people depend on this income?                                                                                 □□ 
11. Percentage of monthly food consumption in monthly gross income in your home (%): □□% 
B. History of main diseases 
B1.History of hypertension 
Yes=1  No=2  Not certain＝9 
 (If your answer is “no” or “not certain”, please go to 
section“B2”) 
□ 
a. Your age when first diagnosed:    N/A=99 □□ 
b. Rank of hospital making such a diagnosis: Province or higher=1  municipal (town)=2  county 
(district)=3  village=4  Not certain=9      N/A=8                                                                                  □ 
  c. Has health professional ever told you the type of hypertension? 
 Essential＝1  Secondary＝2  Not certain＝9  N/A=8 
□ 
  d. So far, the highest level of blood pressure since first diagnosis 
(SBP/DBP mmHg): □□□/□□□ 
  e. Usual blood pressure (SBP/DBP mmHg): □□□/□□□ 
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  f. Drugs you are taking for high blood pressure: Never＝1 Sometimes＝2 Often＝3 Regular＝4  (If 
your answer is “never”, please go to section“B2”)                                □ 
      If yes, how long (months)? □□□ 
  g. Have you taken antihypertensive in past two weeks? (Yes＝1 No＝2) □ 
If yes, drugs name 1.                    2.                       
B2.History of diabetes 
Yes=1   No=2  Not certain＝9 
(If your answer is “no” or “not certain”, please go 
to section“B3”) 
□ 
  a. How old were you when your 
diabetes was first diagnosed? 
□□ 
b. Rank of hospital making such a diagnosis: Province or higher=1  municipal (town)=2  
county (district)=3  village=4  Not certain=9  
  □ 
  c. Fasting blood sugar at 
that time: 
□□.□□mmol/l    or □□□.□ mg/dl  
  d. Primary method you are using for 
glucose control: 
 Dietary control＝1  drugs＝2  Nothing＝3 □ 
  e. Are you using insulin now? Yes＝1    No＝2   Not certain=9 □ 
      If yes, how long (months)?  □□□ 
  f. Are you taking oral hypoglycemic agents? Yes＝1    No＝2 □ 
      If yes, how long (months)? □□□ 
 g. Answered by women only (if you are a man, please go to “h”):   
   Has health professional ever told you that you were 
suffering from diabetes when you were pregnant?  
Yes＝1    No＝2  □ 
   Has health professional ever told you that you were 
suffering from diabetes when you are not pregnant?  
Yes＝1    No＝2 □ 
  h. Has health professional ever told you that you were 
suffering from diabetic ophthalmic disease? 
Yes＝1    No＝2 □ 
  i. Has health professional ever told you that you were 
suffering from diabetic nephritis? 
Yes＝1    No＝2 □ 
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B3. History of 
hyperlipidemia (cholesterol) 
Yes=1   No=2  Not certain＝9 
 (If your answer is “no” or “not certain”, please go 
to section“B4”) 
    □ 
a. Your age when first diagnosed: □□ 
  b. Rank of hospital making such a diagnosis: Province or higher=1  municipal (town)=2  county 
(district)=3  village=4  Not certain=9       □ 
  c. Serum total cholesterol level at that time:  □□□mg/dl  or □□.□mmol/l  
  d. Are you controlling diet or adjusting dietary structure for decreasing blood lipid level 
at present?  Yes＝1   No＝2 
□ 
  e. Did you take antihyperlipidemic drugs within last 2 weeks?   (Yes＝1  No＝2) □ 
If yes, please specify the names    1.                   2.                  
B4. History of obesity 
  a. Your weight at present (Kg): □□□.□ Kg 
    ① Your weight when you were young (25 years old) (Kg): □□□.□ Kg 
    ② Your weight ten years ago (Kg):  □□□.□ Kg 
  b. How old were you when you started 
becoming obese? 
 (If your answer is “no”, please 
print “00”, and then go to “C”) 
□□ 
    ① How many kilograms did you increase in body weight in that year? □□ 
② The most leading cause responsible for your weight increase do you think is: □ 
Diet increase＝1   Exercise decrease＝2   Illness＝3   Drugs＝4   parents obesity＝5 other=6 (Please 
specify)__________________     Not certain＝9   
    ③ Have you ever tried to reduce your weight? (If your 
answer is “no”, please go to “C”) 
Yes＝1    No＝2 □ 
      Main methods you used for weight loss: □，□，□ 
Drug＝1   Dietary control＝2   Exercise increase＝3   surgery＝4 
Chinese medicine＝5   Others=6 (Please specify)____________________ 
      Are you taking any kind of anti-obesity drug at 
present?     (Yes＝1 No＝2) 
□ 
If yes, please specify the names     1.                    2.                       
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C. History of other diseases 
 (Rank of hospital making such a diagnosis: Province or higher=1  municipal (town)=2  county 
(district)=3  village=4  Not certain=9) 
Name of disease 
Suffering from 
this disease 
 (Yes=1 No=2 Not 
certain＝9) 
Your age when first 
diagnosed or attacked 
Rank of hospital 
making such a 
diagnosis 
1. Coronary heart disease □ □□ □ 
a. Myocardial infarction □ □□ □ 
b. Angina □ □□ □ 
c. Heart failure □ □□ □ 
2. Brain stroke □ □□ □ 
Type:                                                                  □ 
1= Subarachnoid Hemorrhage  2= Intracerebral Hemorrhage  3= Thrombotic strokes 4= Embolic 
strokes 5= Uncertain type 
Name of disease 
Suffering from 
this disease 
 (Yes=1 No=2 Not 
certain＝9) 
Your age when first 
diagnosed or attacked 
Rank of hospital 
making such a 
diagnosis 
3. Chronic renal disease □ □□ □ 
4. Chronic gastrointestinal 
diseases 
□ □□ □ 
5.Thyroidism disease □ □□ □ 
6.Cancer □ □□ □ 
7. Polycystic ovary 
syndrome 
□ □□ □ 
8. Premature coronary 
heart disease (before 60 
years old) 
□ □□ □ 
9.Other diseases (    ) □ □□ □ 
D. Family history of disease 
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kinship Total number of hypertension of diabetes of obesity of hyperlipidemia 
Father  □ □ □ □ 
Mother  □ □ □ □ 
Brother □□ □ □ □ □ 
Sister □□ □ □ □ □ 
Son □□ □ □ □ □ 
Daughter □□ □ □ □ □ 
E. Smoking  
1. Have you smoked at least 100 cigarettes up to now? (approximately 5 packs)              □ 
Yes=1   No=2   Stopped=3   (If your answer is “no”, please go to question No.7) 
2.Your age when starting regularly 
smoking (in full years of life)? 
 (at least 1 cigarette everyday, lasting at least half of 
year)                           □□ 
3. How many cigarettes do you smoke in a day? □□ 
4. How many years have you being smoking regularly? □□ 
5. Have you ever tried to stop smoking?      Yes=1   No=2 
If yes, How old were you when you started to stop smoking (in full years of life)? 
  □ 
□□ 
6. Have you ever used other types of tobacco?  Never=1  Dried tobacco=2   Rolling cigarette=3   Snuff 
and chewing tobacco=4                                                    □□ 
7. How many persons smoke at home besides you? None=00    Not certain=99      □□person(s) 
8. How many cigarettes do they smoke in a day on 
average? 
 Not certain=999          □□□Cigarette(s) 
9. For how many hours are you surrounded by smokers 
so near that you can feel that smell during work? (if you 
are unemployed, please select “not applicable”) 
                         □□hours 
None=00   Not applicable=88   Not 
certain=99 
F. Alcohol drinking 
1. Do you ever drink alcohol? (Drinking alcohol twice or more a week, and 1 “liang” (50g) or more 
distilled spirits or equivalent)      □ 
Yes=1     No=2     Stopped=3  (If your answer is “no”, please go to section “G”) 
2. What age were you when you regularly drink alcohol (in full years of life)? (At least 
twice a week, and at least 1 “liang” (50g) distilled spirits) 
□□ 
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3. In the past 12 months, how much different alcohols listed below did you 
drink? (None=00    Not certain=99)  
a. Beer   1bottle of beer=640ml 
1can of beer=355ml □□ Months per year □□Times per month     □bottles per time 
b. Spirits     1“liang”=50ml □□ Months per year□□Times per month □□“liang” per time 
c.Wine   1“liang”=50ml □□ Months per year□□Times per month □□“liang” per time 
d. Rice wine or yellow wine   
1“liang”=50ml □□Months per year □□Times per month□□“liang” per time 
4. Have you ever tried to stop drinking? Yes=1   No=2          □ 
If yes, How old were you (in full years of life) did you start doing this?        □□ 
G. Living habits and physical activity 
1. Average time for exercise in a week (hours)? □□.□hours 
  (If you never exercise, please print“00.0”, and then go to question No.3) 
2. How intensive?        
Strong=1 (Running with weights or running fast, climbing, cycling fast, 
solo tennis) 
Moderate=2 (jogging, field cycling, mild swimming) 
Weak=3 (Walking, Swimming slowly, cycling(static), stretching) 
     
□ 
3. Statistics of average time for activity Weekday (hours) Weekend (hours) 
 
Heavy activity (Running with weights or running fast, 
climbing, cycling fast, solo tennis, farming work, etc) □□ □□ 
 
Moderate activity (jogging, floriculture, field cycling, 
mild swimming, tennis, carpentry, etc) □□ □□ 
 
Light activity (Walking, Swimming slowly, 
cycling(static), stretching, etc) □□ □□ 
 Very low activity (Sitting, Watching TV, Dining, etc) □□ □□ 
 Nothing (Sleeping, lying, etc) □□ □□ 
  Total: 24 hours 
Compared to the past 12 months, how is your level of physical activity in the last month?                        
4. 
1=More  2= Almost  3=Less  9=Unknown                                     □ 
Compared to the majority of others in the same sex and age, how is your level of physical 
activity?                                                                    5. 
1=More  2= Almost  3=Less  9=Unknown                                     □ 
6. 
Compared to yourself ten years ago, how is 
your level of physical activity? 




Now I am asking you some questions about food intake, particularly the frequency of food you 
usually eat. You are supposed to compare the issues in the last year and ten years ago when 
answering these questions. Please tell me the information of food/beverages you eat/drink daily, 





























mutton (Liang) □.□ 1 2 3 4 5 □ □ 
2  Chicken (Liang) □□.□ 1 2 3 4 5 □ □ 
3  
Freshwater fish 
(Liang) □□.□ 1 2 3 4 5 □ □ 
4 Seafood (Liang) □□.□ 1 2 3 4 5 □ □ 
5  Egg (stick) □□ 1 2 3 4 5 □ □ 





□□.□ 1 2 3 4 5 □ □ 
8  
Other vegetables 
(Liang) □□.□ 1 2 3 4 5 □ □ 
9 
Fresh fruits 
(Liang) □□.□ 1 2 3 4 5 □ □ 
10  Pickle (gram) □□.□ 1 2 3 4 5 □ □ 
11  
Fried Food 
(Liang) □□.□ 1 2 3 4 5 □ □ 
12  
Legume (Liang) 
(soy milk, Tofu, 
etc) 
□□.□ 1 2 3 4 5 □ □ 
13  
Green tea 
(Liang) □□.□ 1 2 3 4 5 □ □ 
14  
Black tea 
(Liang) □□.□ 1 2 3 4 5 □ □ 
15  
Flower tea 
(Liang) □□.□ 1 2 3 4 5 □ □ 
I. postscript by investigator 
1. General estimation on the answers of this investigation. □ 
1=believable    2=Almost believable   3= Believable in some degree   4=Not believable 
2. The ending time of investigation:  □□ hours □□ minutes  (24 hours 
system) 
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  Registration Form for Body Examination     
ID number□□□□□ 
1. Have you taken antihypertensive today?               Yes=1    No=2   □ 
2. 
During the past 30 minutes, have you smoked, drank alcohol, drank caffeinated 
beverage, ate anything, exercised intensively?        Yes=1    No=2 □ 
[If the answer to the second question is “yes”, rest for 30 minutes before measuring blood pressure.] 
3. Preparation for blood pressure measurement 
 a. Time record □□ hours□□ minutes (24 hours system) 
 b. Room temperature □□℃ 
Sitting quietly for 5 minutes 
 c. Pulse in 30 seconds □□times in 30 seconds 
4. First blood pressure after 30 seconds SBP/DBP □□□/□□□mmHg 
5. Second blood pressure after 30 seconds SBP/DBP □□□/□□□mmHg 
6. Third blood pressure after 30 seconds SBP/DBP □□□/□□□mmHg 
7. 
Standing height 
(precision in 0.1 cm) 
First measurement:      □□□.□cm 
Second measurement:  □□□.□cm 
8. 
Weight 
(precision in 0.5 kg) 
First measurement:      □□□.□kg 
Second measurement:  □□□.□kg 
First measurement:      □□□.□cm 
9. Waist circumference (precision in 0.1 cm) 
Second measurement:  □□□.□cm 
First measurement:      □□□.□cm 10. Hip circumference (precision in 0.1 cm) 




Investigator’s Signature:               
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Slip of medical examination results 
                ID number：□□□□□ 
 Name                 Sex                  Age 
 
Dear Sir or Madam, 
Thank you very much for your participating in this investigation. What is listed below is your 
medical examination result in this research. We hope that it is helpful to you. Please do not hesitate to 
contact local Investigation Team if you find something wrong. 
 
Measurement Result of this investigation Reference Value 
Height □□□.□cm NA 
Weight □□□.□Kg NA 
Body Mass Index □□.□Kg/m2 
<18.5     Underweight； 
18.5-24.9  Normal； 
>=25     Overweight； 
>=30     Obesity 
Waist Circumference □□□.□cm NA 
Hip Circumference □□□.□cm NA 












Fieldwork Investigation Team, ______Center for Disease Prevention and Control  
200  year   month   day 
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Enquiry about participation in the project “Follow-up Study on Metabolic 
Syndrome and Diabetes in Jiangsu province, China” 
 
This study is a cooperative project between 
Faculty of Medicine, University of Oslo 




During the past 20 years, more and more Chinese people were suffering from chronic 
noncommunicable disease such as diabetes and metabolic syndrome (hypertension, hyperglycemia, 
overweight/obesity, etc). It has been one of main public health problems in China. Furthermore, it is 
especially serious in Jiangsu province due to its relatively developed economics, sustaining increase of 
aging people, and other potential factors. 
 
This is to invite you to participate in a health research, which could help reduce and control the 
occurrence of such diseases and improve the health care quality in our city (town). You were selected 
randomly as a possible participant in this study because our research object is adults (both males and 
females) aged 35~74 years living in our province. The aims of this project are to evaluate the 
prevalence and incidence of metabolic syndrome and to describe the association between metabolic 
syndrome and health outcomes in our province.  
 
If you agree to participate in this research, we will ask you some questions including health status in 
the past, diet, and some other issues like lifestyles. And also, we invite you to provide a blood sample 
for health and biological variables test. Some important results such as blood biochemical indexes will 
be informed to you in time.  
 
There are almost no foreseeable risks for attending this research. By filling in the questionnaire, all you 
need to do is taking about 30 minutes. In the phase of blood examination, possible side effects may 
include local swelling after drawing blood, slight congestion, dizziness, etc. However, we have been 
well prepared to protect you, and to minimize potential harm to the lowest degree. 
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All information collected for the study will be kept strictly confidential, and will be only used for 
research purposes. Anyone unrelated to this study has no access to this information. All of your 
information will have your name and address removed so that you cannot be recognized from it when 
this study is finished. Neither your name nor information which could identify you or any of your will 
never appears in any research reports. Moreover, your participation is completely voluntary. You may 
choose not to participate, or withdraw from it at any time without giving any reason, without your 
medical care or legal rights being affected. Maybe you cannot receive too much direct benefits from 
taking part in this research, but it will have a favorable impact on public health in the future. Your 
participation will contribute greatly to our research. We thank you in advance for agreeing to help us 
out. If you have any questions or concerns about this study, please contact local or Provincial Center 










I have received the information about this study. I (or as legally representative of my dependent on the 
basis that she/he has received the above information and also wishes to participate in this study) hereby 
consent to participating in it. 
 
 
                        
Participant’s (or dependent’s) Signature: _____________ 
                                                                                                         
Date: _____________ 
